Single-dose, ready-to-use injectable formulations

ABSTRACT

Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) 
     
       
         
         
             
             
         
       
     
     including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/418,688, filed Nov. 7, 2016, which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

Provided herein are single-dose, ready-to-use formulations that contain a compound of Formula (I), including pharmaceutically acceptable salts, polymorphs and amorphous forms thereof. Further provided herein are processes for preparing the same.

BACKGROUND

The compound of Formula (I)

N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide, is a Wnt inhibitor. The compound of Formula (I) can be prepared as disclosed in U.S. Pat. No. 8,252,812, incorporated by reference herein in its entirety. The compound of Formula (I), including pharmaceutically acceptable salts and polymorph and amorphous forms thereof can be used in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. There exists a need for formulations containing a compound of Formula (I), including pharmaceutically acceptable salts and polymorph and amorphous forms thereof, such as a ready-to-use, single-dose formulation.

SUMMARY

Provided herein is a process for preparing a single-dose, ready-to-use formulation comprising a compound of Formula (I)

or a pharmaceutically acceptable salt or amorphous or polymorph form thereof, the process comprising:

(a) providing an aqueous solution comprising water;

(b) providing a slurry comprising a compound of Formula (I), or a pharmaceutically acceptable salt or amorphous or polymorph form thereof;

(c) mixing the aqueous solution and the slurry to form a suspension; and

(d) filling a container with the suspension to prepare a single-dose, ready-to-use formulation.

The process provided herein comprises providing an aqueous solution comprising water. In some embodiments of the process provided herein, the aqueous solution comprises a buffer. In some embodiments, the aqueous buffer is a phosphate buffer. In some embodiments, the phosphate buffer is selected from the group consisting of sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, potassium phosphate dibasic, and mixtures thereof. In some embodiments, the phosphate buffer is a mixture of sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate. In some embodiments, the buffer is phosphate buffered saline.

In some embodiments of the process provided herein, the aqueous solution comprises an excipient. In some embodiments, the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof. In some embodiments, the viscosity enhancer is a water-soluble polymer. In some embodiments, the viscosity enhancer is a cellulose derivative. In some embodiments, the cellulose derivative is sodium carboxymethylcellulose. In some embodiments, the aqueous solution comprises about 0.01 g/kg to about 50 g/kg; about 0.5 g/kg to about 50 g/kg; about 1.0 g/kg to about 50 g/kg; about 1 g/kg to about 25 g/kg; about 1 g/kg to about 10 g/kg; about 1 g/kg to about 7.5 g/kg; about 1 g/kg to about 5.5 g/kg; about 1 g/kg to about 2.5 g/kg; about 2.5 g/kg to about 50 g/kg; about 5 g/kg to about 50 g/kg; about 10 g/kg to about 50 g/kg; about 25 g/kg to about 50 g/kg; about. 0.1 to about 5 g/kg; about 2.5 g/kg to about 7.5 g/kg; about 5 g/kg to about 10 g/kg; or about 10 g/kg to about 20 g/kg of a viscosity enhancer. In some embodiments, the aqueous solution comprises about 5.5 g/kg of a cellulose derivative.

In some embodiments of the process provided herein, the surfactant is a polysorbate. In some embodiments, the aqueous solution comprises about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant. In some embodiments, the aqueous solution comprises about 0.5 g/kg of a surfactant. In some embodiments, the aqueous solution comprises about 5.55 g/kg of sodium carboxymethylcellulose and about 0.5 g/kg of polysorbate 80.

The process provided herein comprises providing a slurry comprising a compound of Formula (I), or a pharmaceutically acceptable salt or amorphous or polymorph form thereof. In some embodiments of the process provided herein, the slurry comprises about 0.001 g/kg to about 5 g/kg; about 0.001 g/kg to about 2.5 g/kg; about 0.001 g/kg to about 1 g/kg; about 0.001 g/kg to about 0.75 g/kg; about 0.001 g/kg to about 0.5 g/kg; about 0.001 g/kg to about 0.25 g/kg; about 0.001 g/kg to about 0.01 g/kg; about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof. In some embodiments, the slurry comprises about 0.15 g/kg, about 0.35 g/kg, or about 1.15 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof. In some embodiments, the compound of Formula (I) comprises a polymorph form. In some embodiments, the polymorph is Form 1 and has an X-ray powder diffraction pattern comprising peaks at °2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2. In some embodiments, the compound of Formula (I) comprises a mixture of a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water.

In some embodiments of the process provided herein, the slurry comprises an excipient. In some embodiments, the excipient comprises a surfactant. In some embodiments, the surfactant is a polysorbate. In some embodiments, the slurry comprises about 0.01 g/kg to about 5 g/kg; 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 5 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant. In some embodiments, the slurry comprises about 0.5 g/kg of a surfactant.

In some embodiments of the process provided herein, the slurry comprises about 0.15 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate 80. In some embodiments, the slurry comprises no more than 5% by weight of other Forms. For example, not more than 1% or less than 0.1% of another Form, including amorphous. In some embodiments, the slurry comprises about 0.35 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate 80. In some embodiments, the slurry comprises about 1.15 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate 80.

In some embodiments of the process provided herein, the aqueous solution is a filtered mixture. In some embodiments, the filtered mixture comprises water. In some embodiments, the filtered mixture comprises water and an excipient. In some embodiments, the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof. In some embodiments, the aqueous solution is a sterile filtered mixture. In some embodiments, the aqueous solution is a heat-sterilized mixture.

In some embodiments of the process provided herein, the aqueous solution comprises a sterile diluent.

In some embodiments of the process provided herein, the aqueous solution is a first sterilized mixture; the slurry is a second sterilized mixture; and the process comprises mixing the first sterilized mixture and the second sterilized mixture.

Provided herein is a process comprising mixing the aqueous solution and the slurry to form a suspension. In some embodiments of the process provided herein, the aqueous solution and slurry are mixed to form a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.01 mg/mL to about 2.0 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.5 mg/mL, about 0.01 mg/mL to about 0.2 mg/mL, or about 0.015 mg/mL to about 0.115 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.

Provided herein is a process comprising filling a container with the suspension to prepare a single-dose, ready-to-use formulation. In some embodiments of the process provided herein, the container comprises a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.005 mg/mL to about 2 mg/mL, about 0.001 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 1.8 mg/mL, about 0.015 mg/mL to about 0.115, about 0.025 mg/mL to about 1.6 mg/mL, about 0.05 mg/mL to about 1.5 mg/mL, about 0.075 mg/mL to about 1.25 mg/mL, about 0.1 mg/mL to about 1 mg/mL, or about 0.25 mg/mL to about 0.75 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof. In some embodiments, the container is selected from the group consisting of a vial, a bottle, an ampule, and a syringe. In some embodiments, the vial is a glass vial or a plastic vial made of polyethylene, polypropylene, polyolefins, polyethylene terephthalate, polyethylene terephthalate G, poly(vinyl chloride), and mixtures thereof. In some embodiments, the container has a volume of 1 mL, 2 mL, 3 mL, 4 mL, or 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL. In some embodiments, the container is a 3 mL polypropylene vial.

In some embodiments of the process provided herein, the mixing is done aseptically.

In some embodiments of the process provided herein, the filling is done aseptically.

In some embodiments, the process further comprises terminally sterilizing the filled container containing the suspension. In some embodiments, the container is terminally sterilized when the suspension comprises about 0.05 mg/mL to about 10 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof. For example, the suspension comprises about 0.05 mg/mL to about 5 mg/mL, about 0.05 mg/mL to about 2.5 mg/mL, about 0.05 mg/mL to about 1 mg/mL, about 0.05 mg/mL to about 0.5 mg/mL, about 0.05 mg/mL to about 0.1 mg/mL, about 0.1 mg/mL to about 10 mg/mL, about 0.1 mg/mL to about 5 mg/mL, about 0.1 mg/mL to about 2.5 mg/mL, about 0.1 mg/mL to about 1 mg/mL, about 0.1 mg/mL to about 0.5 mg/mL, about 0.1 mg/mL to about 0.25 mg/mL, about 0.25 mg/mL to about 10 mg/mL, about 0.25 mg/mL to about 5 mg/mL, about 0.25 mg/mL to about 2.5 mg/mL, about 0.25 mg/mL to about 1 mg/mL, about 0.25 mg/mL to about 0.5 mg/mL, bout 0.5 mg/mL to about 10 mg/mL, about 0.5 mg/mL to about 5 mg/mL, about 0.5 mg/mL to about 2.5 mg/mL, about 0.5 mg/mL to about 1 mg/mL, about 1 mg/mL to about 10 mg/mL, about 1 mg/mL to about 5 mg/mL, about 1 mg/mL to about 2.5 mg/mL, about 2.5 mg/mL to about 10 mg/mL, about 2.5 mg/mL to about 5 mg/mL, or about 5 mg/mL to about 10 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.

Also provided herein is a single-dose, ready-to-use formulation comprising a compound of Formula (I)

or a pharmaceutically acceptable salt or amorphous or polymorph form thereof, prepared by a process comprising:

(a) providing an aqueous solution comprising water;

(b) providing a slurry comprising a compound of Formula (I), or a pharmaceutically acceptable salt or amorphous or polymorph form thereof;

(c) mixing the aqueous solution and the slurry to form a suspension; and

(d) filling a container with the suspension to prepare a single-dose, ready-to-use formulation.

The single-dose, ready-to-use formulation prepared by the process provided herein comprises providing an aqueous solution comprising water. In some embodiments, the aqueous solution comprises a buffer. In some embodiments, the aqueous buffer is a phosphate buffer. In some embodiments, the phosphate buffer is selected from the group consisting of sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, potassium phosphate dibasic, and mixtures thereof. In some embodiments, the phosphate buffer is a mixture of sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate. In some embodiments, the buffer is phosphate buffered saline.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the aqueous solution comprises an excipient. In some embodiments, the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof. In some embodiments, the viscosity enhancer is a cellulose derivative. In some embodiments, the cellulose derivative is a water-soluble cellulose derivative. In some embodiments, the cellulose derivative is sodium carboxymethylcellulose. In some embodiments, the aqueous solution comprises about 0.01 g/kg to about 50 g/kg; about 0.5 g/kg to about 50 g/kg; about 1.0 g/kg to about 50 g/kg; about 1 g/kg to about 25 g/kg; about 1 g/kg to about 10 g/kg; about 1 g/kg to about 7.5 g/kg; about 1 g/kg to about 5.5 g/kg; about 1 g/kg to about 2.5 g/kg; about 2.5 g/kg to about 50 g/kg; about 5 g/kg to about 50 g/kg; about 10 g/kg to about 50 g/kg; about 25 g/kg to about 50 g/kg; about 0.1 g/kg to about 5 g/kg; about 2.5 g/kg to about 7.5 g/kg; about 5 g/kg to about 10 g/kg; or about 10 g/kg to about 20 g/kg of a viscosity enhancer. In some embodiments, the aqueous solution comprises about 5.5 g/kg of a cellulose derivative.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the surfactant is a polysorbate. In some embodiments, the aqueous solution comprises about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant. In some embodiments, the aqueous solution comprises about 0.5 g/kg of a surfactant. In some embodiments, the aqueous solution comprises about 5.55 g/kg of sodium carboxymethylcellulose and about 0.5 g/kg of polysorbate 80.

The single-dose, ready-to-use formulation prepared by the process provided herein comprises providing a slurry comprising a compound of Formula (I), or a pharmaceutically acceptable salt or amorphous or polymorph form thereof. In some embodiments of the process provided herein, the slurry comprises about 0.001 g/kg to about 5 g/kg; about 0.001 g/kg to about 2.5 g/kg; about 0.001 g/kg to about 1 g/kg; about 0.001 g/kg to about 0.75 g/kg; about 0.001 g/kg to about 0.5 g/kg; about 0.001 g/kg to about 0.25 g/kg; about 0.001 g/kg to about 0.01 g/kg; about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof. In some embodiments, the slurry comprises about 0.15 g/kg, about 0.35 g/kg, or about 1.15 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof. In some embodiments, the compound of Formula (I) comprises a polymorph form. In some embodiments, the polymorph is Form 1 and has an X-ray powder diffraction pattern comprising peaks at °2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2. In some embodiments, the compound of Formula (I) comprises a mixture of a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the compound comprises no more than 5% by weight of other Forms. For example, not more than 1% or less than 0.1% of another Form, including amorphous.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the slurry comprises an excipient. In some embodiments, the excipient comprises a surfactant. In some embodiments, the surfactant is a polysorbate. In some embodiments, the slurry comprises about 0.01 g/kg to about 5 g/kg; 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 5 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant. In some embodiments, the slurry comprises about 0.5 g/kg of a surfactant.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the slurry comprises about 0.15 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate 80. In some embodiments, the slurry comprises about 0.35 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate 80. In some embodiments, the slurry comprises about 1.15 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate 80.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the aqueous solution is a filtered mixture. In some embodiments, the filtered mixture comprises water. In some embodiments, the filtered mixture comprises water and an excipient. In some embodiments, the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the aqueous solution comprises a sterile diluent.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the aqueous solution is a sterile-filtered mixture or a first bulk sterilized mixture or both; the slurry is a second bulk sterilized mixture; and the process comprises mixing the first bulk sterilized mixture and the second bulk sterilized mixture.

Provided herein is a single-dose, ready-to-use formulation prepared by a process comprising mixing the aqueous solution and the slurry to form a suspension. In some embodiments, the aqueous solution and slurry are mixed to form a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.001 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 2.0 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.5 mg/mL, about 0.01 mg/mL to about 0.2 mg/mL, or about 0.015 mg/mL to about 0.115 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.

Provided herein is a single-dose, ready-to-use formulation prepared by a process comprising filling a container with the suspension to prepare a single-dose, ready-to-use formulation. In some embodiments, the container comprises a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.005 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 1.8 mg/mL, about 0.015 mg/mL to about 0.115, about 0.025 mg/mL to about 1.6 mg/mL, about 0.05 mg/mL to about 1.5 mg/mL, about 0.075 mg/mL to about 1.25 mg/mL, about 0.1 mg/mL to about 1 mg/mL, or about 0.25 mg/mL to about 0.75 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof. In some embodiments, the container is selected from the group consisting of a vial, a bottle, an ampule, and a syringe. In some embodiments, the vial is a glass vial or a plastic vial made of polyethylene, polypropylene, polyolefins, polyethylene terephthalate, polyethylene terephthalate G, poly(vinyl chloride), and mixtures thereof. In some embodiments, the container has a volume of 1 mL, 2 mL, 3 mL, 4 mL, or 5 mL. In some embodiments, the container is a 3 mL polypropylene vial.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the mixing is done aseptically.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the filling is done aseptically.

In some embodiments of the single-dose, ready-to-use formulation prepared by the process provided herein, the container containing the suspension is terminally sterilized. In some embodiments, the container is terminally sterilized when the suspension comprises about 0.05 mg/mL to about 10 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof. For example, the suspension comprises about 0.05 mg/mL to about 5 mg/mL, about 0.05 mg/mL to about 2.5 mg/mL, about 0.05 mg/mL to about 1 mg/mL, about 0.05 mg/mL to about 0.5 mg/mL, about 0.05 mg/mL to about 0.1 mg/mL, about 0.1 mg/mL to about 10 mg/mL, about 0.1 mg/mL to about 5 mg/mL, about 0.1 mg/mL to about 2.5 mg/mL, about 0.1 mg/mL to about 1 mg/mL, about 0.1 mg/mL to about 0.5 mg/mL, about 0.1 mg/mL to about 0.25 mg/mL, about 0.25 mg/mL to about 10 mg/mL, about 0.25 mg/mL to about 5 mg/mL, about 0.25 mg/mL to about 2.5 mg/mL, about 0.25 mg/mL to about 1 mg/mL, about 0.25 mg/mL to about 0.5 mg/mL, bout 0.5 mg/mL to about 10 mg/mL, about 0.5 mg/mL to about 5 mg/mL, about 0.5 mg/mL to about 2.5 mg/mL, about 0.5 mg/mL to about 1 mg/mL, about 1 mg/mL to about 10 mg/mL, about 1 mg/mL to about 5 mg/mL, about 1 mg/mL to about 2.5 mg/mL, about 2.5 mg/mL to about 10 mg/mL, about 2.5 mg/mL to about 5 mg/mL, or about 5 mg/mL to about 10 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.

Also provided herein is a method for treating osteoarthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the single-dose, ready-to-use formulation prepared by the process provided herein that comprises a therapeutically effective amount of a compound of Formula (I), including salt and amorphous and polymorph forms thereof. In some embodiments, administration of the formulation is intra-articular. In some embodiments, the formulation is administered to the subject once. In some embodiments, the formulation is administered more than once with each injection separated by about 3 months to about 60 months. In some embodiments, the formulation is administered once every 2 weeks, every 3 weeks, every 4 weeks, every 6 weeks, every 8 weeks, or every 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, or 60 months.

Other features and advantages of the processes, formulations, and uses provided herein will be apparent from the following detailed description and figures, and from the claims.

DESCRIPTION OF DRAWINGS

FIGS. 1A-1D are scans of polymorph Form 1 of the compound of Formula (I). FIG. 1A is an x-ray powder diffraction scan of fully dried Form 1. FIG. 1B is a differential scanning calorimetry scan of Form 1. FIG. 1C is a thermal gravimetric analysis scan of Form 1. FIG. 1D is a dynamic vapor sorption scan of Form 1.

FIGS. 2A-2H are scans of polymorph Forms 2, 2*, and 2** of the compound of Formula (I). FIG. 2A is an x-ray powder diffraction scan of fully dried Form 2. FIG. 2B is a differential scanning calorimetry scan of Form 2. FIG. 2C is a thermal gravimetric analysis scan of Form 2. FIG. 2D is an x-ray powder diffraction scan of fully dried Form 2*. FIG. 2E is a differential scanning calorimetry scan of Form 2*. FIG. 2F is a thermal gravimetric analysis scan of Form 2*. FIG. 2G is an x-ray powder diffraction scan of Form 2**. FIG. 2H is a differential scanning calorimetry scan of Form 2**.

FIGS. 3A-3C are scans of polymorph Form 3 of the compound of Formula (I). FIG. 3A is an x-ray powder diffraction scan of fully dried Form 3. FIG. 3B is a differential scanning calorimetry scan of Form 3. FIG. 3C is a thermal gravimetric analysis scan of Form 3.

FIGS. 4A-4I are scans of polymorph Forms 4, 4*, and 4** of the compound of Formula (I). FIG. 4A is an x-ray powder diffraction scan of fully dried Form 4. FIG. 4B is a differential scanning calorimetry scan of Form 4. FIG. 4C is a thermal gravimetric analysis scan of Form 4. FIG. 4D is an x-ray powder diffraction scan of fully dried Form 4*. FIG. 4E is a differential scanning calorimetry scan of Form 4*. FIG. 4F is a thermal gravimetric analysis scan of Form 4*. FIG. 4G is an x-ray powder diffraction scan of Form 4**. FIG. 4H is a differential scanning calorimetry scan of Form 4**. FIG. 4I is a thermal gravimetric analysis scan of Form 4**.

FIGS. 5A-5D are scans of polymorph Forms 5 and 5* of the compound of Formula (I). FIG. 5A is an x-ray powder diffraction scan of fully dried Form 5. FIG. 5B is a differential scanning calorimetry scan of Form 5. FIG. 5C is a thermal gravimetric analysis scan of Form 5. FIG. 5D is an x-ray powder diffraction scan of Form 5*.

FIGS. 6A and 6B are scans of polymorph Form 6 of the compound of Formula (I). FIG. 6A is an x-ray powder diffraction scan of Form 6. FIG. 6B is a differential scanning calorimetry scan of Form 6.

FIGS. 7A-7C are scans of polymorph Form 7 of the compound of Formula (I). FIG. 7A is an x-ray powder diffraction scan of fully dried Form 7. FIG. 7B is a differential scanning calorimetry scan of Form 7. FIG. 7C is a thermal gravimetric analysis scan of Form 7.

FIGS. 8A-8C are scans of polymorph Form 8 of the compound of Formula (I). FIG. 8A is an x-ray powder diffraction scan of fully dried Form 8. FIG. 8B is a differential scanning calorimetry scan of Form 8. FIG. 8C is a thermal gravimetric analysis scan of Form 8.

FIGS. 9A-9D are scans of polymorph Form 9 of the compound of Formula (I). FIG. 9A is an x-ray powder diffraction scan of fully dried Form 9. FIG. 9B is a differential scanning calorimetry scan of Form 9. FIG. 9C is a thermal gravimetric analysis scan of Form 9. FIG. 9D is a dynamic vapor sorption scan of Form 9.

FIGS. 10A-10E are scans of polymorph Forms 10 and 10* of the compound of Formula (I). FIG. 10A is an x-ray powder diffraction scan of fully dried Form 10. FIG. 10B is a differential scanning calorimetry scan of Form 10. FIG. 10C is a thermal gravimetric analysis scan of Form 10. FIG. 10D is an x-ray powder diffraction scan of Form 10*. FIG. 10E is a differential scanning calorimetry scan of Form 10*.

FIGS. 11A-11F are scans of polymorph Forms 11 and 11* of the compound of Formula (I). FIG. 11A is an x-ray powder diffraction scan of fully dried Form 11. FIG. 11B is a differential scanning calorimetry scan of Form 11. FIG. 11C is a thermal gravimetric analysis scan of Form 11. FIG. 11D is an x-ray powder diffraction scan of fully dried Form 11*. FIG. 11E is a differential scanning calorimetry scan of Form 11*. FIG. 11F is a thermal gravimetric analysis scan of Form 11*.

FIGS. 12A-12C are scans of Form 12, an example of a non-stoichiometric hydrate of polymorph Form 1 of the compound of Formula (I). FIG. 12A is an x-ray powder diffraction scan of Form 12. FIG. 12B is a differential scanning calorimetry scan of Form 12. FIG. 12C is a thermal gravimetric analysis scan of Form 12.

FIGS. 13A-13D are scans of Form 13, an example of a non-stoichiometric hydrate of polymorph Form 1 of the compound of Formula (I). FIG. 13A is an x-ray powder diffraction scan of Form 13. FIG. 13B is a differential scanning calorimetry scan of Form 13. FIG. 13C is a thermal gravimetric analysis scan of Form 13. FIG. 13D is a dynamic vapor sorption scan of Form 13.

FIG. 14 is a flow chart showing an exemplary process described herein.

FIGS. 15A-15D are scans of Form 1 in the presence of increasing relative humidity (RH), an example of a non-stoichiometric or stoichiometric hydrate of polymorph Form 1 of the compound of Formula (I). FIG. 15A is an x-ray powder diffraction scan of Form 1 exposed to 10% RH as the anhydrous Form 1. FIG. 15B is an x-ray powder diffraction scan of Form 1 exposed to 20% RH as a partial hydrate of Form 1. FIG. 15C is an x-ray powder diffraction scan of Form 1 exposed to 30% RH as a hydrate of Form 1 (≈10-12% water uptake). FIG. 15D is an x-ray powder diffraction scan of Form 1 exposed to 90% RH as a full hydrate of Form 1 (≈17-20% water uptake).

DETAILED DESCRIPTION 1. Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Methods and materials are described herein for use in the present disclosure; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic formulations is contemplated. Supplementary active ingredients can also be incorporated into the formulations. In addition, various excipients, such as are commonly used in the art, can be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, N.J. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (2010); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 12th Ed., The McGraw-Hill Companies.

As used herein, a “single-dose” refers to a sterile formulation that is packaged in a container for parenteral administration (injection or infusion). A single-dose formulation is designed for use with a single patient as a single injection/infusion. Examples of containers for use with single-dose formulations include vials, ampules, bottles, and syringes.

“Ready-to-use,” as used herein, refers to a formulation that does not require constitution or dilution with a prescribed amount of diluent, e.g., water for injection or other suitable diluent, before use by the designated route. For example, a formulation in a vial, of the desired concentration, that only needs to be drawn up into a syringe.

The term “polymorph,” as used herein, refers to crystals of the same molecule having different physical properties as a result of the order of the molecules in the crystal lattice. Polymorphs of a single compound have one or more different chemical, physical, mechanical, electrical, thermodynamic, and/or biological properties from each other. Differences in physical properties exhibited by polymorphs can affect pharmaceutical parameters such as storage stability, compressibility, density (important in composition and product manufacturing), dissolution rates (an important factor in determining bio-availability), solubility, melting point, chemical stability, physical stability, powder flowability, water sorption, compaction, and particle morphology. Differences in stability can result from changes in chemical reactivity (e.g. differential oxidation, such that a dosage form discolors more rapidly when comprised of one polymorph than when comprised of another polymorph) or mechanical changes (e.g., crystal changes on storage as a kinetically favored polymorph converts to a thermodynamically more stable polymorph) or both (e.g., one polymorph is more hygroscopic than the other). As a result of solubility/dissolution differences, some transitions affect potency and/or toxicity. In addition, the physical properties of the crystal may be important in processing; for example, one polymorph might be more likely to form solvates or might be difficult to filter and wash free of impurities (i.e., particle shape and size distribution might be different between one polymorph relative to the other). “Polymorph” does not include amorphous forms of the compound. As used herein, “amorphous” refers to a non-crystalline form of a compound which may be a solid state form of the compound or a solubilized form of the compound. For example, “amorphous” refers to a compound without a regularly repeating arrangement of molecules or external face planes.

The term “anhydrous,” as used herein, refers to a crystal form of the compound of Formula (I) that has 1% or less by weight water. For example, 0.5% or less, 0.25% or less, or 0.1% or less by weight water.

The term “solvate” as used herein refers to a crystalline form of a compound of Formula (I), such as a polymorph form of the compound, where the crystal lattice comprises one or more solvents of crystallization.

The term “non-stoichiometric hydrate” refers to a crystalline form of a compound of Formula I that comprises water, but wherein variations in the water content do not cause significant changes to the crystal structure. In some embodiments, a non-stoichiometric hydrate can refer to a crystalline form of a compound of Formula I that has channels or networks throughout the crystal structure into which water molecules can diffuse. During drying of non-stoichiometric hydrates, a considerable proportion of water can be removed without significantly disturbing the crystal network, and the crystals can subsequently rehydrate to give the initial non-stoichiometric hydrated crystalline form. Unlike stoichiometric hydrates, the dehydration and rehydration of non-stoichiometric hydrates is not accompanied by a phase transition, and thus all hydration states of a non-stoichiometric hydrate represent the same crystal form. In some embodiments, a non-stoichiometric hydrate can have up to about 20% by weight water, such as, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or greater than 1% water by weight. In some embodiments, a non-stoichiometric hydrate can have between 1% and about 20% by weight water, such as between 1% and about 5%, 1% and about 10%, 1% and about 15%, about 2% and about 5%, about 2% and about 10%, about 2% and about 15%, about 2% and about 20%, about 5% and about 10%, about 5% and about 15%, about 5% and about 20%, about 10% and about 15%, about 10% and about 20%, or about 15% and about 20% by weight water.

In some embodiments the % water by weight in a crystal form, such as a non-stoichiometric or stoichiometric hydrate, is determined by the Karl Fischer titration method. In some embodiments, the crystal form is dried prior to Karl Fischer titration.

“Purity,” when used in reference to a composition including a polymorph of a compound of Formula (I), refers to the percentage of one specific polymorph form relative to another polymorph form or an amorphous form of a compound of Formula (I) in the referenced composition. For example, a composition comprising polymorph Form 1 having a purity of 90% would comprise 90 weight parts Form 1 and 10 weight parts of other polymorph and/or amorphous forms of the compound of Formula (I).

As used herein, a compound or composition is “substantially free of” one or more other components if the compound or composition contains no significant amount of such other components. Such components can include starting materials, residual solvents, or any other impurities that can result from the preparation of and/or isolation of the compounds and compositions provided herein. In some embodiments, a polymorph form provided herein is substantially free of other polymorph forms. In some embodiments, a particular polymorph of the compound of Formula (I) is “substantially free” of other polymorphs if the particular polymorph constitutes at least about 95% by weight of the compound of Formula (I) present. In some embodiments, a particular polymorph of the compound of Formula (I) is “substantially free” of other polymorphs if the particular polymorph constitutes at least about 97%, about 98%, about 99%, or about 99.5% by weight of the compound of Formula (I) present. In certain embodiments, a particular polymorph of the compound of Formula (I) is “substantially free” of water if the amount of water constitutes no more than about 2%, about 1%, or about 0.5% by weight of the polymorph.

As used herein, a compound is “substantially present” as a given polymorph if at least about 50% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 60% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 70% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 80% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 90% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 95% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 96% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 97% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 98% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 99% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 99.5% by weight of the compound is in the form of that polymorph.

“Room temperature” or “RT” refers to the ambient temperature of a typical laboratory, which is typically around 25° C.

The term “administration” or “administering” refers to a method of giving a dosage of a compound or pharmaceutical formulation to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian. The preferred method of administration can vary depending on various factors, e.g., the components of the pharmaceutical formulation, the site of the disease, and the severity of the disease.

“Subject,” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the subject is a human.

As used herein, “therapeutically effective amount” is an amount of the formulation provided herein comprising a compound of Formula (I), or salt or amorphous or polymorph form thereof, which is sufficient to achieve the desired effect and can vary according to the nature and severity of the disease condition, and the potency of the compound. A therapeutic effect is the relief, to some extent, of one or more of the symptoms of the disease, and can include curing a disease. “Curing” means that the symptoms of active disease are eliminated. However, certain long-term or permanent effects of the disease can exist even after a cure is obtained (such as, e.g., extensive tissue damage).

“Treat,” “treatment,” or “treating,” as used herein, refers to administering a compound or pharmaceutical formulation as provided herein for therapeutic purposes. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease, thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, preventing additional symptoms, ameliorating the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder and/or reducing the severity of symptoms that will or are expected to develop.

2. Process for Preparing Single-Dose, Ready-to-Use Formulations

Provided herein is a process for preparing a single-dose, ready-to-use formulation comprising a compound of Formula (I)

including salts and amorphous and polymorph forms thereof. The process includes:

(a) providing an aqueous solution comprising water;

(b) providing a slurry comprising a compound of Formula (I), including salts and amorphous and polymorph forms thereof;

(c) mixing the aqueous solution and slurry to form a suspension; and

(d) aseptically filling a container with the suspension to prepare a single-dose formulation.

In the process provided herein, the process comprises providing an aqueous solution comprising water. Suitable types of water include, but are not limited to, deionized water, distilled water, reverse osmosis filtered water, reagent grade water, water for injection (WFI), USP/EP grade water suitable for use in pharmaceuticals, and aqueous buffer solutions. The water is substantially free of contaminants, such as parasites, pathogens, chemical contaminants, and particulate contamination. In some embodiments, the aqueous solution comprises a buffer. In some embodiments, the aqueous solution comprises an excipient. In some embodiments, the aqueous solution comprises a buffer and an excipient. In some embodiments, the excipient comprises a surfactant. In some embodiments, the excipient comprises a viscosity enhancer. In some embodiments, the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof. For example, the aqueous solution can include a surfactant and a viscosity enhancer in an aqueous buffer. In some embodiments, the viscosity enhancer is a cellulose derivative. In some embodiments, the aqueous solution comprises about 5.55 g/kg of sodium carboxymethylcellulose and about 0.5 g/kg of polysorbate 80 in phosphate buffered saline.

In some embodiments of the process provided herein, the aqueous solution includes a viscosity enhancer. The viscosity enhancer can be, for example, a cellulose or cellulose derivative or a synthetic polymer. Examples of viscosity enhancers include, but are not limited to, microcrystalline cellulose (Avicel: Asahi Kasei Corp., etc.), microcrystalline cellulose carmellose sodium (Avicel RC: Asahi Kasei Corp., etc.), methyl cellulose (Metolose SM: Shin-Etsu Chemical Co., Ltd., etc.), ethyl cellulose (Ethocel: Dow Chemical Co., etc.), hydroxypropyl cellulose (Nisso HPC: Nippon Soda Co., Ltd., etc.), low-substituted hydroxypropyl cellulose (L-HPC: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose 2208 (Metolose 90SH: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose 2906 (Metolose 65SH: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose 2910 (Metolose 60SH: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl cellulose phthalate 200731 (HPMCP: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl cellulose phthalate 220824 (HPMCP: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose acetate succinate (Shin-Etsu AQOAT: Shin-Etsu Chemical Co., Ltd., etc.), carmellose (NS-300: Gotoku Chemical Co., Ltd., etc.), carmellose calcium (ECG-505: Gotoku Chemical Co., Ltd., etc.), carmellose sodium (Cellogen: Daiichi Kogyo Seiyaku Co., Ltd., etc.), croscarmellose sodium (Ac-Di-Sol: Asahi Kasei Corp., etc.), carboxymethyl ethyl cellulose (CMEC: Freund Corp., etc.), cellulose acetate phthalate (CAP: Wako Pure Chemical Industries, Ltd., etc.), hydroxyethyl cellulose (NATROSOL: Aqualon Corp., etc.), polyvinyl alcohol, polyvinylpyrrolidone, or mixtures thereof. In some embodiments, the viscosity enhancer is a cellulose derivative. In some embodiments, the cellulose derivative is a water-soluble cellulose or water-soluble cellulose derivative. In some embodiments, the cellulose derivative is a carboxymethylcellulose, or a pharmaceutically acceptable salt thereof. For example, the aqueous solution comprises sodium carboxymethylcellulose.

A viscosity enhancer can be present in the aqueous solution in an amount of about 0.01 g/kg to about 50 g/kg of the aqueous solution. For example, about 0.01 g/kg to about 25 g/kg; about 0.01 g/kg to about 5 g/kg; about 0.1 g/kg to about 50 g/kg; about 0.1 g/kg to about 25 g/kg; about 0.1 g/kg to about 5 g/kg; about 0.5 g/kg to about 50 g/kg; about 0.5 g/kg to about 0.25 g/kg; about 0.5 g/kg to about 10 g/kg; about 0.5 g/kg to about 7.5 g/kg; about 0.5 g/kg to about 5.5 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 1 g/kg to about 50 g/kg; about 1 g/kg to about 25 g/kg; about 1 g/kg to about 10 g/kg; about 1 g/kg to about 7.5 g/kg; about 1 g/kg to about 5.5 g/kg; about 1 g/kg to about 2.5 g/kg; about 2.5 g/kg to about 50 g/kg; about 5 g/kg to about 50 g/kg; about 10 g/kg to about 50 g/kg; about 25 g/kg to about 50 g/kg; about 0.1 g/kg to about 5 g/kg; about 2.5 g/kg to about 7.5 g/kg; about 5 g/kg to about 10 g/kg; and about 10 g/kg to about 20 g/kg of the aqueous solution. In some embodiments, the viscosity enhancer can be present in the aqueous solution at about 5 g/kg of the aqueous solution. In some embodiments, the viscosity enhancer can be present in the aqueous solution at about 5.55 g/kg of the aqueous solution. For example, the aqueous solution comprises about 5.55 g/kg sodium carboxymethylcellulose. In some embodiments, a cellulose derivative is present in the aqueous solution in an amount of about 0.05% to about 5% by weight of the aqueous solution. For example, about 0.05% to about 2.5%; about 0.05% to about 1%; about 0.05% to about 0.75%; about 0.05% to about 0.55%; about 0.05% to about 0.25%; about 0.1% to about 5%; about 0.1% to about 2.5%; about 0.1% to about 1%; about 0.1% to about 0.75%; about 0.1% to about 0.55%; about 0.1% to about 0.25%; about 0.25% to about 5%; about 0.5% to about 5%; about 1% to about 5%; about 2.5% to about 5%; about 0.25% to about 0.75%; about 0.5% to about 1%; and about 1% to about 2% by weight of the aqueous solution. In some embodiments, the viscosity enhancer can be present in the aqueous solution at about 0.55% by weight of the aqueous solution. For example, the aqueous solution comprises about 0.55% sodium carboxymethylcellulose by weight.

In some embodiments of the process provided herein, the aqueous solution includes a surfactant. Examples of surfactants include, but are not limited to, polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85; polyoxyethylene hydrogenated castor oils such as polyoxyethylene hydrogenated castor oil 60 and polyoxyl 35 castor oil; sorbitan fatty acid esters; sucrose fatty acid esters; polyoxyethylene polyoxypropylene glycols; polyoxyethylene fatty acid ethers; polyoxyl stearates; phosphatidylcholines; phosphatidylglycerols, including, but not limited to phosphatidylglycerols containing fatty acids, fatty alcohols, or a combination thereof, and carbon chain lengths between 4 and 20 carbons; and other surfactants, including, but not limited to, 1,2-dimyristoyl-sn-glycero-3-(phospho-s-(1-glycerol)), 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), 1,2-di stearoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), 1,2-di stearoyl-sn-glycero-3-phosphocholine, deoxycholic acid, dipalmitoylphosphatidylglycerol (dl), distearoylphosphatidylcholine (dl), docusate sodium, egg phospholipids, glyceryl palmitostearate, glyceryl trioleate, hydrogenated soybean lecithin, hydrolyzed soy protein (enzymatic; 2000 mw), hydroxyethylpiperazine ethane sulfonic acid, lecithin, miripirium chloride, n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phiv, oleic acid, palmitic acid, peg vegetable oil, peg-20 sorbitan isostearate, peg-40 castor oil, phospholipid, poloxamer 188, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 3350, polyethylene glycol 400, polyethylene glycol 4000, polyethylene glycol 600, polyoxyethylene fatty acid esters, sodium cholesteryl sulfate, sodium deoxycholate, sodium n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glyc, sodium oleate, sorbitan monolaurate, sorbitan monopalmitate, stearic acid, tricaprylin, or mixtures thereof. In some embodiments, the surfactant is a polysorbate. For example, the aqueous solution comprises polysorbate 80.

A surfactant can be present in the aqueous solution in an amount of about 0.01 g/kg to about 5 g/kg of the aqueous solution. In some embodiments, the concentration of surfactant depends on the critical micelle concentration of the individual surfactant. In some embodiments, the amount of surfactant is enough to be above the critical micelle concentration of the surfactant, enough to coat the surface area of the particles, or both. For example, about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; about 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; and about 1 g/kg to about 2 g/kg of the aqueous solution. In some embodiments, the surfactant can be present in the aqueous solution at about 0.5 g/kg of the aqueous solution. For example, the aqueous solution comprises about 0.5 g/kg polysorbate 80. In some embodiments, a surfactant can be present in the aqueous solution in an amount of about 0.001% to about 0.5% by weight of the aqueous solution. For example, about 0.001% to about 0.25%; about 0.001% to about 0.1%; about 0.001% to about 0.075%; about 0.001% to about 0.05%; about 0.001% to about 0.025%; about 0.0025% to about 0.5%; about 0.005% to about 0.5%; about 0.1% to about 0.5%; about 0.01% to about 0.5%; about 0.01% to about 0.25%; about 0.01% to about 0.1%; about 0.01% to about 0.075%; about 0.01% to about 0.05%; about 0.01% to about 0.025%; about 0.025% to about 0.5%; about 0.05% to about 0.5%; about 0.1% to about 0.5%; about 0.025% to about 0.5%; about 0.025% to about 2.5%; about 0.025% to about 0.075%; about 0.05% to about 2.5%; about 0.05% to about 0.1%; and about 0.1% to about 0.2% by weight of the aqueous solution. In some embodiments, the surfactant can be present in the aqueous solution at about 0.05% by weight of the aqueous solution. For example, the aqueous solution comprises about 0.05% polysorbate 80 by weight.

In the process provided herein, the process comprises providing a slurry comprising a compound of Formula (I), including salts and amorphous and polymorph forms thereof. In some embodiments, the compound of Formula (I) is polymorph Form 1. In some embodiments, the compound of Formula (I) is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the slurry comprises a surfactant. In some embodiments, the slurry comprises water. For example, the slurry can include a compound of Formula (I), including salts and amorphous and polymorph forms thereof and a surfactant in water.

The compound of Formula (I), including salts and amorphous and polymorph forms thereof can be present in the slurry in an amount of about 0.001 g/kg to about 5 g/kg of the slurry. For example, about 0.001 g/kg to about 5 g/kg; about 0.001 g/kg to about 2.5 g/kg; about 0.001 g/kg to about 1 g/kg; about 0.001 g/kg to about 0.75 g/kg; about 0.001 g/kg to about 0.5 g/kg; about 0.001 g/kg to about 0.25 g/kg; about 0.001 g/kg to about 0.01 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; and about 1 g/kg to about 2 g/kg of the slurry. In some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, can be present in the slurry at about 0.15 g/kg of the slurry. In some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, can be present in the slurry at about 0.35 g/kg of the slurry. In some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, can be present in the slurry at about 1.15 g/kg of the slurry. In some embodiments, the slurry comprises about 0.15 g/kg polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the slurry comprises about 0.35 g/kg polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the slurry comprises about 1.15 g/kg polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water.

In some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, can be present in the slurry in an amount of about 0.0001% to about 0.5% by weight of the slurry. For example, about 0.0001% to about 0.5%; about 0.0001% to about 0.25%; about 0.0001% to about 0.1%; about 0.0001% to about 0.075%; about 0.0001% to about 0.05%; about 0.0001% to about 0.025%; about 0.0001% to about 0.001%; about 0.001% to about 0.5%; about 0.001% to about 0.25%; about 0.001% to about 0.1%; about 0.001% to about 0.075%; about 0.001% to about 0.05%; about 0.001% to about 0.025%; about 0.01% to about 0.25%; about 0.01% to about 0.1%; about 0.01% to about 0.075%; about 0.01% to about 0.05%; about 0.01% to about 0.025%; about 0.025% to about 0.5%; about 0.05% to about 0.5%; about 0.1% to about 0.5%; about 0.25% to about 0.5%; about 0.025% to about 0.075%; about 0.05% to about 0.1%; and about 0.1% to about 0.2% by weight of the slurry. In some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, can be present in the slurry at about 0.015% by weight of the slurry. For example, the slurry comprises about 0.015% by weight of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, can be present in the slurry at about 0.035% by weight of the slurry. For example, the slurry comprises about 0.035% by weight of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, can be present in the slurry at about 0.115% by weight of the slurry. For example, the slurry comprises about 0.115% by weight of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water.

In some embodiments, the slurry comprises about 0.15 g/kg of a compound of Formula (I), e.g., Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate 80 in water. In some embodiments, the compounds has no more than 5% by weight of other Forms. For example, not more than 1% or less than 0.1% of any additional Form, including amorphous. In some embodiments, the slurry comprises about 0.35 g/kg of a compound of Formula (I), e.g., Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water, and about 0.5 g/kg of polysorbate 80 in water. In some embodiments, the slurry comprises about 1.15 g/kg of a compound of Formula (I), e.g., Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water, and about 0.5 g/kg of polysorbate 80 in water.

In some embodiments, the slurry comprises water. Suitable types of water include, but are not limited to, deionized water, distilled water, reverse osmosis filtered water, reagent grade water, water for injection (WFI), USP grade water suitable for use in pharmaceuticals, and aqueous buffer solutions. The water is substantially free of contaminants, such as parasites, pathogens, chemical contaminants, and particulate contamination. In some embodiments, the slurry comprises water for injection.

In the process provided herein, the process comprises mixing the aqueous solution and slurry to form a suspension. In some embodiments, the aqueous solution is added to the slurry. In some embodiments, the slurry is added to the aqueous solution. In some embodiments, the aqueous solution and the slurry are added to a container substantially at the same time.

In some embodiments, the aqueous solution is a filtered mixture. In some embodiments, the filtered mixture comprises water. In some embodiments, the filtered mixture comprises water and an excipient. In some embodiments, the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof. In some embodiments, the filtered mixture is prepared by filtering the aqueous solution through a 0.2 μm filter. In some embodiments, the filter comprises a membrane comprising cellulose acetate, cellulose nitrate, nylon, a polymer, such as polyethersulfone or polytetrafluorethylene, regenerated cellulose, or glass. In some embodiments, the filter membrane is a polymeric membrane. In some embodiments, the filter membrane is a polyethersulfone (PES) membrane. In some embodiments, a sterile diluent is mixed with the filtered mixture.

In some embodiments, the aqueous solution, the slurry, or both, are sterilized. In some embodiments, sterilization is by heat. In some embodiments, sterilization is by bulk steam sterilization. In some embodiments, sterilization is by dry heat sterilization. In some embodiments, sterilization is by irradiation. In some embodiments, sterilization is by filtration. In some embodiments, sterilization is by bulk steam sterilization, dry heat sterilization, irradiation, or combinations thereof. In some embodiments, the aqueous solution is sterilized by filtration or by heat or by a combination of filtration and heat. In some embodiments, the aqueous solution is sterilized to form a first sterilized mixture prior to mixing with the slurry. In some embodiments, the filtered mixture is sterilized prior to mixing with the slurry. In some embodiments, the filtered mixture is aseptically mixed with sterile diluent and sterilized prior to mixing with the slurry. In some embodiments, the slurry is sterilized to form a second sterilized mixture prior to mixing with the aqueous solution. In some embodiments, the slurry is sterilized by heat. In some embodiments, the aqueous solution is sterilized to form a first sterilized mixture and the slurry is sterilized to form a second sterilized mixture prior to mixing.

In some embodiments, the aqueous solution and the slurry are mixed aseptically to form a suspension. The mixing can be done with any sterile diluent or solution for injection. For example, any commercially available sterile diluent or solution for injection can be used. In some embodiments, the sterile solution for injection includes, but is not limited to, saline, with or without potassium chloride, e.g., a 0.9% saline solution, dextrose, e.g., a 5% dextrose solution, phosphate buffer, Lactated Ringer's solution, and combinations thereof. In some embodiments, the sterile solution for injection is a commercially available solution containing hyaluronic acid or hyaluronic acid derivatives. In some embodiments, the sterile diluent is aseptically added in an amount sufficient to result in a suspension comprising 0.015 mg/mL of the compound of Formula (I) including salts and amorphous and polymorph forms thereof. In some embodiments, the sterile diluent is aseptically added in an amount sufficient to result in a suspension comprising 0.035 mg/mL of the compound of Formula (I) including salts and amorphous and polymorph forms thereof. In some embodiments, the sterile diluent is aseptically added in an amount sufficient to result in a suspension comprising 0.115 mg/mL of the compound of Formula (I) including salts and amorphous and polymorph forms thereof.

In the process provided herein, the aqueous solution and slurry are mixed to form a suspension. For example, in some embodiments, the compound of Formula (I), including salts and amorphous and polymorph forms thereof, is not completely dissolved in the aqueous phase of the suspension. In the process provided herein, the suspension comprises about 0.005 mg/mL to about 2.5 mg/mL, about 0.01 mg/mL to about 2.0 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.5 mg/mL, about 0.01 mg/mL to about 0.2 mg/mL, or about 0.015 mg/mL to about 0.115 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof. In some embodiments, the suspension comprises 0.015 mg/mL of the compound of Formula (I) including salts and amorphous and polymorph forms thereof. In some embodiments, the suspension comprises 0.035 mg/mL of the compound of Formula (I) including salts and amorphous and polymorph forms thereof. In some embodiments, the suspension comprises 0.115 mg/mL of the compound of Formula (I) including salts and amorphous and polymorph forms thereof.

In some embodiments of the process provided herein, the aqueous solution, the slurry, the suspension, or combination thereof, are prepared in tanks. For example, the tank can be a tank used for manufacturing. In some embodiments, the tank is a stainless steel tank. In some embodiments, the tanks are jacketed for steam. In some embodiments, the tanks are equipped with one or more mixers, for example, a standard mixer and/or homogenizer, which are used to mix the ingredients added to the tank. In some embodiments, the tank is equipped with a heating and/or cooling device. In some embodiments, the tanks comprise ports for addition, recirculation equipment, transfer equipment, mixers, heating and/or cooling equipment, and combinations thereof. In some embodiments, the tanks have a capacity between about 5 L and about 5000 L. In some embodiments, the tanks have a capacity between about 5 L and about 3000 L; about 5 L and about 2000 L; about 5 L and about 1000 L; about 5 L and about 500 L; about 5 L and about 300 L; about 5 L and about 150 L; about 5 L and about 100 L; about 5 L and about 50 L; about 5 L and about 30 L; about 5 L and about 20 L; about 20 L and about 5000 L; about 20 L and about 3000 L; about 20 L and about 2000 L; about 20 L and about 1000 L; about 20 L and about 500 L; about 20 L and about 300 L; about 20 L and about 150 L; about 20 L and about 100 L; about 20 L and about 50 L; about 20 L and about 30 L; about 30 L and about 5000 L; about 30 L and about 3000 L; about 30 L and about 2000 L; about 30 L and about 1000 L; about 30 L and about 500 L; about 30 L and about 300 L; about 30 L and about 150 L; about 30 L and about 100 L; about 30 L and about 50 L; about 50 L and about 5000 L; about 50 L and about 3000 L; about 50 L and about 2000 L; about 50 L and about 1000 L; about 50 L and about 500 L; about 50 L and about 300 L; about 50 L and about 150 L; about 50 L and about 100 L; about 100 L and about 5000 L; about 100 L and about 3000 L; about 100 L and about 2000 L; about 100 L and about 1000 L; about 100 L and about 500 L; about 100 L and about 300 L; about 100 L and about 150 L; about 150 L and about 5000 L; about 150 L and about 3000 L; about 150 L and about 2000 L; about 150 L and about 1000 L; about 150 L and about 500 L; about 150 L and about 300 L; about 300 L and about 5000 L; about 300 L and about 3000 L; about 300 L and about 2000 L; about 300 L and about 1000 L; about 300 L and about 500 L; about 500 L and about 5000 L; about 500 L and about 3000 L; about 500 L and about 2000 L; about 500 L and about 1000 L; about 1000 L and about 5000 L; about 1000 L and about 3000 L; about 1000 L and about 2000 L; about 2000 L and about 5000 L; about 2000 L and about 3000 L; or about 3000 L and about 5000 L. In some embodiments, the tank has a capacity of about 5000 L, about 3000 L, about 2000 L, about 1000 L, about 500 L, about 300 L, about 150 L, about 100 L, about 50 L, about 30 L, about 20 L, or about 5 L. Other size tanks are known and can be used with the provided process.

In some embodiments, the process is performed using a scaled-up manufacturing process. A scaled-up manufacturing process can be used for volumes greater than 1 L or about 1 L or greater than 1 gallon or about 1 gallon, for example, greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, or more liters.

In the process provided herein, the process comprises aseptically filling a container with the suspension to prepare a single-dose, ready-to-use formulation. Examples of containers include, but are not limited to, vials, bottles, ampules, and syringes. In some embodiments, the suspension is aseptically filled into a single-use vial (i.e., unused portions of each vial are discarded and not saved for later administration). In some embodiments, the vial is a plastic vial. For example, the vial can be made of polyethylene, polypropylene, polyolefins, polyethylene terephthalate, polyethylene terephthalate G, poly(vinyl chloride), and mixtures thereof. In some embodiments, the vial is a polypropylene vial. In some embodiments, the vial is a glass vial. The container can be any size that can fit the desired amount of the formulation. For example, the container can be a 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL container. In some embodiments, the container is a 3 mL vial. In some embodiments, the container is a 5 mL vial. In some embodiments, the container is a 3 mL polypropylene vial. For example, a polypropylene vial that is made using blow-fill-seal technology. In some embodiments, the vial is designed for easy withdrawal of the formulation with a syringe. In some embodiments, the vial has a Luer slip design. In some embodiments, the vial has a Luer lock design.

The resulting single-dose, ready-to-use formulations produced by the process provided herein are filled into containers comprising between about 0.005 mg/mL and about 2.5 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof, for example, between about 0.005 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 1.8 mg/mL, about 0.015 mg/mL to about 0.115, about 0.025 mg/mL to about 1.6 mg/mL, about 0.05 mg/mL to about 1.5 mg/mL, about 0.075 mg/mL to about 1.25 mg/mL, about 0.1 mg/mL to about 1 mg/mL, or about 0.25 mg/mL to about 0.75 mg/mL. In some embodiments, the containers comprise a formulation comprising about 0.015 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the containers comprise a formulation comprising about 0.035 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the containers comprise a formulation comprising about 0.115 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the containers comprise a concentration between about 0.1 mg/mL and 4 mg/mL. In some embodiments, the concentration is 2 mg/mL.

In some embodiments, the process further comprises terminally sterilizing the container containing the suspension. For example, the sterilization can be performed at 121.1° C. (250° F.) or at lower temperatures, for example, between about 70-100° C., to achieve an F_(o) of NLT 2. In some embodiments, the NLT is greater than 10 or greater than 30. In some embodiments, the container is terminally sterilized when the suspension comprises about 0.05 mg/mL to about 10 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof. For example, the suspension comprises about 0.05 mg/mL to about 5 mg/mL, about 0.05 mg/mL to about 2.5 mg/mL, about 0.05 mg/mL to about 1 mg/mL, about 0.05 mg/mL to about 0.5 mg/mL, about 0.05 mg/mL to about 0.1 mg/mL, about 0.1 mg/mL to about 10 mg/mL, about 0.1 mg/mL to about 5 mg/mL, about 0.1 mg/mL to about 2.5 mg/mL, about 0.1 mg/mL to about 1 mg/mL, about 0.1 mg/mL to about 0.5 mg/mL, about 0.1 mg/mL to about 0.25 mg/mL, about 0.25 mg/mL to about 10 mg/mL, about 0.25 mg/mL to about 5 mg/mL, about 0.25 mg/mL to about 2.5 mg/mL, about 0.25 mg/mL to about 1 mg/mL, about 0.25 mg/mL to about 0.5 mg/mL, bout 0.5 mg/mL to about 10 mg/mL, about 0.5 mg/mL to about 5 mg/mL, about 0.5 mg/mL to about 2.5 mg/mL, about 0.5 mg/mL to about 1 mg/mL, about 1 mg/mL to about 10 mg/mL, about 1 mg/mL to about 5 mg/mL, about 1 mg/mL to about 2.5 mg/mL, about 2.5 mg/mL to about 10 mg/mL, about 2.5 mg/mL to about 5 mg/mL, or about 5 mg/mL to about 10 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.

In some embodiments, the process further comprises labeling the containers. In some embodiments, the process further comprises packaging the containers, for example, into boxes, cartons, or pre-formed blisters. In some embodiments, the process further comprises labeling the boxes, cartons, or preformed blisters.

3. Single-Dose, Ready-to-Use Formulations

Provided herein are single-dose, ready-to-use pharmaceutical formulations comprising a compound of Formula (I), including pharmaceutically acceptable salts and amorphous and polymorph forms thereof, prepared by the process described herein. In some embodiments, the formulations are prepared as single-dose formulations. Provided herein are pharmaceutical formulations prepared from a polymorph form of a compound of Formula (I). In some embodiments, the polymorph form is Form 1. In some embodiments, the polymorph form is a mixture of Form 1 and Form 9. In some embodiments, the polymorph is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulation comprises a polymorph form of a compound of Formula (I). In some embodiments, the polymorph form is Form 1. In some embodiments, the pharmaceutical formulation comprises a polymorph form of a compound of Formula (I) that is a mixture of forms. In some embodiments, the mixture of forms is a mixture of Forms 1 and 9. In some embodiments, the pharmaceutical formulation comprises a polymorph form of a compound of Formula (I) that is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein contains polymorph Form 1 that has a purity of at least about 90% (not including water or solvents). In some embodiments, the purity is at least about 95%. In some embodiments, the purity is at least about 98%. For example, the purity is at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the formulation comprising Form 1 is substantially free of other forms of the compound of Formula (I), e.g., Form 9. In some embodiments, the formulation contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, 0.01%, or 0.001% by weight of other forms of the compound of Formula (I). In some embodiments, the other forms of the compound of Formula (I) are other anhydrous forms of the compound of Formula (I). In some embodiments, the formulation contains less than about 15% by weight of one or more other compounds of Formula (I). For example, the formulation contains less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, 0.01%, or 0.001% by weight of one or more other forms of the compound of Formula (I). For example, the formulation can contain less than about 15% by weight of Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or combinations of two or more thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein contains a non-stoichiometric or stoichiometric hydrate of polymorph Form 1 having between 1% and about 20% by weight water that has a purity of at least about 90%. In some embodiments, the purity is at least about 95%. In some embodiments, the purity is at least about 98%. For example, the purity is at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the formulation comprising the non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water is substantially free of other forms of the compound of Formula (I), e.g., Form 9. In some embodiments, the formulation contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, 0.01%, or 0.001% by weight of other forms of the compound of Formula (I). In some embodiments, the other forms of the compound of Formula (I) are other anhydrous forms of the compound of Formula (I). In some embodiments, the formulation contains less than about 15% by weight of one or more other compounds of Formula (I). For example, the formulation contains less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, 0.01%, or 0.001% by weight of one or more other forms of the compound of Formula (I). For example, the formulation can contain less than about 15% by weight of Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11, or combinations of two or more thereof.

In some embodiments, the single-dose, ready-to-use formulation prepared by the process provided herein comprises about 0.001 mg to about 5.0 mg per injection of a compound of Formula (I), including amorphous and polymorph forms thereof. For example, the formulation in some embodiments comprises about 0.001 mg to about 4 mg, about 0.001 mg to about 3 mg, about 0.001 mg to about 2 mg, about 0.001 mg to about 1 mg, about 0.001 mg to about 0.5 mg, 0.001 mg to about 0.4 mg, about 0.001 mg to about 0.3 mg, about 0.001 mg to about 0.25 mg, about 0.001 mg to about 0.2 mg, about 0.001 mg to about 0.15 mg, about 0.001 mg to about 0.1 mg, about 0.001 mg to about 0.075 mg, about 0.001 mg to about 0.055 mg, about 0.001 mg to about 0.05 mg, about 0.001 mg to about 0.035 mg, about 0.001 mg to about 0.025 mg, about 0.001 mg to about 0.01 mg, about 0.001 mg to about 0.005 mg, about 0.005 mg to about 5.0 mg, about 0.0075 mg to about 5.0 mg, about 0.01 mg to about 5.0 mg, about 0.01 mg to about 4.0 mg, about 0.01 mg to about 3.0 mg, about 0.01 mg to about 2.0 mg, about 0.01 mg to about 1.0 mg, about 0.01 mg to about 0.7 mg, about 0.01 mg to about 0.5 mg, about 0.01 mg to about 0.3 mg, about 0.01 mg to about 0.23 mg, about 0.01 mg to about 0.1 mg, about 0.01 mg to about 0.07 mg, about 0.01 mg to about 0.05 mg, about 0.01 mg to about 0.03 mg, about 0.03 mg to about 4.0 mg, about 0.03 mg to about 3.0 mg, about 0.03 mg to about 2.0 mg, about 0.03 mg to about 1.0 mg, about 0.03 mg to about 0.7 mg, about 0.03 mg to about 0.5 mg, about 0.03 mg to about 0.3 mg, about 0.03 mg to about 0.23 mg, about 0.03 mg to about 0.1 mg, about 0.03 mg to about 0.07 mg, about 0.03 mg to about 0.05 mg, about 0.07 mg to about 4.0 mg, about 0.07 mg to about 3.0 mg, about 0.07 mg to about 2.0 mg, about 0.07 mg to about 1.0 mg, about 0.07 mg to about 0.7 mg, about 0.07 mg to about 0.5 mg, about 0.07 mg to about 0.3 mg, about 0.07 mg to about 0.23 mg, about 0.07 mg to about 0.1 mg, about 0.025 mg to about 5.0 mg, about 0.045 mg to about 5.0 mg, about 0.05 mg to about 5.0 mg, about 0.075 mg to about 5.0 mg, about 0.1 mg to about 5.0 mg, about 0.25 mg to about 5.0 mg, about 0.01 mg to about 3.0 mg, about 0.025 mg to about 2.0 mg, about 0.01 mg to about 0.1 mg, and about 0.15 mg to about 0.25 mg of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the formulation comprises about 0.001 mg, 0.005 mg, 0.01 mg, 0.03 mg, 0.05 mg, 0.07 mg, 0.1 mg, 0.23 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1.0 mg, 1.2 mg, 1.5 mg, 1.7 mg, 2.0 mg, 2.2 mg, 2.5 mg, 2.7 mg, 3.0 mg, 3.2 mg, 3.5 mg, 3.7 mg, 4.0 mg, 4.2 mg, 4.5 mg, 4.7 mg, or 5.0 mg of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the single-dose, ready-to-use formulation comprises 0.03 mg of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the single-dose, ready-to-use formulation comprises 0.07 mg of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the single-dose, ready-to-use formulation comprises 0.115 mg of the compound of Formula (I), including amorphous and polymorph forms thereof.

The single-dose, ready-to-use formulations prepared by the process provided herein comprising a compound of Formula (I), including salts and amorphous and polymorph forms thereof, can comprise a conventional pharmaceutical carrier, excipient, or the like. In some embodiments, the compounds of Formula (I), including salts and amorphous and polymorph forms thereof, are formulated as a suspension. For example, the compound of Formula (I) is not completely dissolved in the pharmaceutically acceptable carrier, i.e., the compound of Formula (I) is suspended in the pharmaceutically acceptable carrier. In some embodiments, the formulation comprises the compound of Formula (I) suspended in a pharmaceutically acceptable carrier. In some embodiments, the formulation comprises a polymorph form of Formula (I) suspended in a pharmaceutically acceptable carrier. In some embodiments, the formulation comprises Form 1 suspended in a pharmaceutically acceptable carrier. In some embodiments, the formulation comprises a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water suspended in a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical formulation is a solution, i.e., the compound of Formula (I) is completely dissolved in the pharmaceutically acceptable carrier.

In some embodiments, the polymorph form is dried prior to mixing with the pharmaceutically acceptable carrier.

In some embodiments, the single-dose, ready-to-use pharmaceutically administrable formulations comprising a compound of Formula (I), including amorphous and polymorph forms thereof, can optionally comprise pharmaceutical excipients in a carrier, e.g., water, saline, buffer, aqueous dextrose, mannitol, glycerol, glycols, ethanol or the like, to form a suspension. If desired, the pharmaceutical formulation can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents, and the like.

In some embodiments, a single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises water. Suitable types of water include, but are not limited to, deionized water, distilled water, reverse osmosis filtered water, reagent grade water, water for injection (WFI), USP/EP grade water suitable for use in pharmaceuticals, and aqueous buffer solutions. The water is substantially free of contaminants, such as parasites, pathogens, chemical contaminants, and particulate contamination. For example, the pharmaceutical formulation can include an aqueous buffer solution. Examples of buffer agents include, but are not limited to, acetic acid, acetic anhydride, adipic acid, alanine, albumin, alcohol, alfadex, ammonia, ammonium acetate, ammonium sulfate, anhydrous citric acid, anhydrous dextrose, anhydrous lactose, anhydrous trisodium citrate, arginine, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, calcium chloride, calcium gluceptate, calcium hydroxide, calcium, caprylic acid, carbon dioxide, citric acid monohydrate, dibasic potassium phosphate, diethanolamine, disodium citrate sesquihydrate, disodium hydrogen citrate, edetate calcium disodium, edetate disodium, edetate sodium, edetic acid, ethanolamine hydrochloride, ferric chloride, gluceptate sodium, glycine hydrochloride, glycine, guanidine hydrochloride, histidine, hydrochloric acid, isoleucine, lactic acid, lactobionic acid, leucine, lysine acetate, lysine, lysine monohydrate, magnesium chloride, magnesium stearate, maleic acid, metaphosphoric acid, methanesulfonic acid, nitric acid, phosphate ion, phosphoric acid, potassium chloride, potassium hydroxide, potassium phosphate (monobasic), sodium acetate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium bisulfate, sodium carbonate, sodium citrate, sodium hydroxide, sodium hypochlorite, sodium phosphate dihydrate, sodium phosphate, sodium phosphate p-32, sodium phosphate dibasic dihydrate, sodium phosphate dibasic dodecahydrate, sodium phosphate dibasic, sodium phosphate dibasic (anhydrous), sodium phosphate dibasic heptahydrate, sodium phosphate monobasic (anhydrous), sodium phosphate monobasic dihydrate, sodium phosphate monobasic monohydrate, sodium phosphate monobasic, sodium sulfate (anhydrous), sodium sulfate, sodium thioglycolate, sodium thiomalate, sodium thiosulfate, succinic acid, sulfuric acid, tartaric acid, tartaric acid (dl), trifluoroacetic acid, tromantadine, and tromethamine. In some embodiments, the pharmaceutical formulation comprises phosphate buffered saline.

In some embodiments, a single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises a viscosity enhancer. The viscosity enhancer can be, for example, a cellulose or cellulose derivative or a synthetic polymer. Examples of viscosity enhancers include, but are not limited to, microcrystalline cellulose (Avicel: Asahi Kasei Corp., etc.), microcrystalline cellulose carmellose sodium (Avicel RC: Asahi Kasei Corp., etc.), methyl cellulose (Metolose SM: Shin-Etsu Chemical Co., Ltd., etc.), ethyl cellulose (Ethocel: Dow Chemical Co., etc.), hydroxypropyl cellulose (Nisso HPC: Nippon Soda Co., Ltd., etc.), low-substituted hydroxypropyl cellulose (L-HPC: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose 2208 (Metolose 90SH: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose 2906 (Metolose 65SH: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose 2910 (Metolose 60SH: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl cellulose phthalate 200731 (HPMCP: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl cellulose phthalate 220824 (HPMCP: Shin-Etsu Chemical Co., Ltd., etc.), hydroxypropyl methyl cellulose acetate succinate (Shin-Etsu AQOAT: Shin-Etsu Chemical Co., Ltd., etc.), carmellose (NS-300: Gotoku Chemical Co., Ltd., etc.), carmellose calcium (ECG-505: Gotoku Chemical Co., Ltd., etc.), carmellose sodium (Cellogen: Daiichi Kogyo Seiyaku Co., Ltd., etc.), croscarmellose sodium (Ac-Di-Sol: Asahi Kasei Corp., etc.), carboxymethyl ethyl cellulose (CMEC: Freund Corp., etc.), cellulose acetate phthalate (CAP: Wako Pure Chemical Industries, Ltd., etc.), hydroxyethyl cellulose (NATROSOL: Aqualon Corp., etc.), polyvinyl alcohol, polyvinylpyrrolidone, or mixtures thereof. In some embodiments, the viscosity enhancer is a cellulose derivative. In some embodiments, the cellulose derivative is a water-soluble cellulose or water-soluble cellulose derivative. In some embodiments, a cellulose derivative is a carboxymethylcellulose, or a pharmaceutically acceptable salt thereof. For example, a cellulose derivative is sodium carboxymethylcellulose. A viscosity enhancer can be present in the formulation in an amount of about 0.1% to about 5% by weight of the formulation. For example, about 0.1% to about 2.5%; about 0.1% to about 1%; about 0.1% to about 0.75%; about 0.1% to about 0.5%; about 0.1% to about 0.25%; about 0.25% to about 5%; about 0.5% to about 5%; about 1% to about 5%; about 2.5% to about 5%; about 0.25% to about 0.75%; about 0.5% to about 1%; and about 1% to about 2% by weight of the formulation. In some embodiments, the viscosity enhancer can be present in the formulation at about 0.5% by weight of the formulation. In some embodiments, the viscosity enhancer is a cellulose derivative and is present in the formulation at about 0.5% by weight of the formulation.

In some embodiments, a single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises a surfactant. Non-limiting examples of surfactants include polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85; polyoxyethylene hydrogenated castor oils such as polyoxyethylene hydrogenated castor oil 60 and polyoxyl 35 castor oil; sorbitan fatty acid esters; sucrose fatty acid esters; polyoxyethylene polyoxypropylene glycols; polyoxyethylene fatty acid ethers; polyoxyl stearates; phosphatidylcholines; phosphatidylglycerols, including, but not limited to phosphatidylglycerols containing fatty acids, fatty alcohols, or a combination thereof, and carbon chain lengths between 4 and 20 carbons; and other surfactants, including, but not limited to, 1,2-dimyristoyl-sn-glycero-3-(phospho-s-(1-glycerol)), 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), 1,2-di stearoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), 1,2-di stearoyl-sn-glycero-3-phosphocholine, deoxycholic acid, dipalmitoylphosphatidylglycerol (dl), distearoylphosphatidylcholine (dl), docusate sodium, egg phospholipids, glyceryl palmitostearate, glyceryl trioleate, hydrogenated soybean lecithin, hydrolyzed soy protein (enzymatic; 2000 mw), hydroxyethylpiperazine ethane sulfonic acid, lecithin, miripirium chloride, n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phiv, oleic acid, palmitic acid, peg vegetable oil, peg-20 sorbitan isostearate, peg-40 castor oil, phospholipid, poloxamer 188, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 3350, polyethylene glycol 400, polyethylene glycol 4000, polyethylene glycol 600, polyoxyethylene fatty acid esters, sodium cholesteryl sulfate, sodium deoxycholate, sodium n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glyc, sodium oleate, sorbitan monolaurate, sorbitan monopalmitate, stearic acid, tricaprylin, or mixtures thereof. In some embodiments, the surfactant is a polysorbate. For example, the pharmaceutical formulation comprises polysorbate 80. A surfactant can be present in the formulation in an amount of about 0.001% to about 0.5% by weight of the formulation. In some embodiments, the concentration of surfactant depends on the critical micelle concentration of the individual surfactant. In some embodiments, the amount of surfactant is enough to be above the critical micelle concentration of the surfactant, enough to coat the surface area of the particles, or both. For example, about 0.001% to about 0.25%; about 0.001% to about 0.1%; about 0.001% to about 0.075%; about 0.001% to about 0.05%; about 0.001% to about 0.025%; about 0.0025% to about 0.5%; about 0.005% to about 0.5%; about 0.1% to about 0.5%; about 0.01% to about 0.5%; about 0.01% to about 0.25%; about 0.01% to about 0.1%; about 0.01% to about 0.075%; about 0.01% to about 0.05%; about 0.01% to about 0.025%; about 0.025% to about 0.5%; about 0.05% to about 0.5%; about 0.1% to about 0.5%; about 0.025% to about 0.5%; about 0.025% to about 2.5%; about 0.025% to about 0.075%; about 0.05% to about 2.5%; about 0.05% to about 0.1%; and about 0.1% to about 0.2% by weight of the formulation. In some embodiments, the surfactant can be present in the formulation at about 0.05% by weight of the formulation.

In some embodiments, a single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises a compound of Formula (I), including amorphous and polymorph forms thereof, and a pharmaceutically acceptable carrier. For example, the formulation comprises a compound of Formula (I) and saline, e.g., phosphate buffered saline. In some embodiments, the pharmaceutical formulation comprises a compound of Formula (I), a pharmaceutically acceptable carrier, and one or more excipients. For example, the formulation comprises a compound of Formula (I), a pharmaceutically acceptable carrier, e.g., phosphate buffered saline, and one or more excipients, e.g., a surfactant and a cellulose derivative. In some embodiments, the surfactant is a polysorbate, e.g., polysorbate 80. In some embodiments, the cellulose derivative is sodium carboxymethylcellulose. In some embodiments, the pharmaceutical formulation comprises a compound of Formula (I), e.g., a polymorph form of Formula (I), e.g., Form 1, a pharmaceutically acceptable carrier, e.g., phosphate buffered saline, and one or more excipients, e.g., sodium carboxymethylcellulose and a polysorbate, e.g., polysorbate 80.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises a compound of Formula (I), e.g., a polymorph form of Formula (I), about 0.01% to about 5% by weight of a cellulose derivative, and about 0.01% to about 0.5% by weight of a surfactant in an aqueous buffer. For example, a pharmaceutical formulation provided herein can include a compound of Formula (I), e.g., Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water, about 0.5% by weight sodium carboxymethylcellulose and about 0.05% by weight polysorbate 80 in phosphate buffered saline.

In some embodiments, a single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein has a pH of about 6.0 to about 8.0. For example, a pharmaceutical formulation can have a pH of about 7.3 or 7.4. In some embodiments a pharmaceutical formulation provided herein has a pH of about 3.0 to about 5.0. For example, a pharmaceutical formulation can have a pH of about 3.8.

The single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein can contain an excipient. The term “excipient” is used herein to describe any ingredient other than the compound(s) provided herein, e.g., compound of Formula (I), including polymorph and amorphous forms thereof. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat, solubilizers, tonicity agents, stabilizers, preservatives, salt formation substances, chelators/chelating agents, viscosity enhancers, contrast agent, anti-foam agents, control release agents, lubricants, adhesives, analgesics, antiheparins, antivirals, colorants, emollients, propellants, and other excipients, including, but not limited to activated charcoal, barium sulfate, bibapcitide, brocrinat, calcobutrol, glutathione, zinc, zinc acetate, zinc carbonate, zinc chloride, and zinc oxide. Cyclodextrins such as α-, β, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-b-cyclodextrins, or other solubilized derivatives can also be advantageously used to enhance delivery of compounds described herein. Dosage forms or formulations containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated formulations can contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art; for example, see Remington: The Science and Practice of Pharmacy, 22^(nd) Edition (Pharmaceutical Press, London, U K. 2012).

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a solubilizer. Examples of solubilizers include, but are not limited to, acetyltryptophan (dl), alanine, albumin (aggregated), alcohol, alfadex intracavitary powder, ammonia, anhydrous dextrose, anhydrous lactose, anhydrous trisodium citrate, arginine, ascorbic acid, aspartic acid, benzenesulfonic acid, benzyl alcohol, benzyl benzoate, benzyl chloride, betadex sulfobutyl ether sodium, butanol (mixed isomers), caprylic acid, carboxymethylcellulose, carboxymethylcellulose sodium, castor oil, cholesterol, corn oil, cottonseed oil, creatine, creatinine, croscarmellose sodium, crospovidone, cysteine hydrochloride, cysteine, cysteine (dl), dextran 40, dextran, diacetylated monoglycerides, diethanolamine, dimethyl sulfoxide, ethanolamine hydrochloride, ethyl acetate, ethylene-vinyl acetate copolymer (15% vinyl acetate), gamma cyclodextrin, gelatin, gentisic acid ethanolamide, gentisic acid, gluconolactone, glucuronic acid, glycerin, hetastarch, human albumin microspheres, hyaluronate sodium, hydroxypropyl betadex intramuscular injection, hypromellose, isopropyl alcohol, methylcellulose, methylpyrrolidone, microcrystalline cellulose, N,N-dimethylacetamide, niacinamide, oleic acid, palmitic acid, peanut oil, peg vegetable oil, peg-20 sorbitan isostearate, peg-40 castor oil, phenylethyl alcohol, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 3350, polyethylene glycol 400, polyethylene glycol 4000, polyethylene glycol 600, polypropylene glycol, polyvinyl alcohol, poppy seed oil, povidone k12, povidone k17, povidone, proline, propyl gallate, propylene glycol, sesame oil, soybean oil, starch, stearic acid, trimethylsilyl treated dimethiconol/trimethylsiloxysilicate crosspolymer, and yellow wax, and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a tonicity agent. Examples of tonicity agents include, but are not limited to, dextrose monohydrate, dextrose solution, dextrose, dimethyl sulfoxide, fructose, gluconolactone, glucuronic acid, glycerin, glycine hydrochloride, glycine, guanidine hydrochloride, histidine, hydrochloric acid, hypertonic sodium chloride solution, isoleucine, isopropyl alcohol, isotonic sodium chloride solution, lactic acid (dl), lactobionic acid, lactose monohydrate, lactose, leucine, lysine acetate, lysine, lysine monohydrate, magnesium chloride, magnesium stearate, maleic acid, mannitol, meglumine, methionine, methylboronic acid, polypropylene glycol, potassium chloride, potassium hydroxide, potassium phosphate (monobasic), proline, propyl gallate, propylene glycol, saccharin sodium, serine, sodium acetate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium bisulfate, sodium carbonate, sodium chloride, sodium citrate, sodium gluconate, sodium hydroxide, sodium hypochlorite, sodium lactate, sodium phosphate dihydrate, sodium phosphate, sodium phosphate p-32, sodium phosphate dibasic dihydrate, sodium phosphate dibasic dodecahydrate, sodium phosphate dibasic, sodium phosphate dibasic (anhydrous), sodium phosphate dibasic heptahydrate, sodium phosphate monobasic (anhydrous), sodium phosphate monobasic dihydrate, sodium phosphate monobasic monohydrate, sodium phosphate monobasic, sodium sulfate (anhydrous), sodium sulfate, sodium thioglycolate, sodium thiomalate, sodium thiosulfate, sorbitol, succinic acid, sucrose, sulfuric acid, tartaric acid, tartaric acid (dl), threonine, trehalose, trifluoroacetic acid, trisodium citrate dihydrate, tromethamine, tryptophan, tyrosine, urea, urethane, and valine and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a stabilizer. Examples of stabilizers include, but are not limited to, acetyltryptophan (dl), alanine, albumin (aggregated), alcohol, alfadex intracavitary powder, ammonia, anhydrous dextrose, anhydrous lactose, anhydrous trisodium citrate, arginine, ascorbic acid, aspartic acid, benzenesulfonic acid, benzyl alcohol, benzyl benzoate, benzyl chloride, betadex sulfobutyl ether sodium, boric acid, butanol (mixed isomers), caprylic acid, carboxymethylcellulose, carboxymethylcellulose sodium, castor oil, cholesterol, creatine, creatinine, croscarmellose sodium, crospovidone, cysteine hydrochloride, cysteine, cysteine (dl), dextran 40, dextran, ethylene-vinyl acetate copolymer (15% vinyl acetate), gelatin, gentisic acid ethanolamide, gentisic acid, hetastarch, human albumin microspheres, hyaluronate sodium, hypromellose, meglumine, methionine, methylboronic acid, methylcellulose, methylpyrrolidone, microcrystalline cellulose, miripirium chloride, n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-di stearoyl-sn-glycero-3-phiv, N,N-dimethylacetamide, niacinamide, phenylalanine, polyvinyl alcohol, povidone K12, povidone K17, povidone, serine, sodium citrate, sodium gluconate, sodium lactate, starch, threonine, trehalose, tricaprylin, trimethylsilyl treated dimethiconol/trimethylsiloxysilicate crosspolymer, trisodium citrate dihydrate, tryptophan, tyrosine, urea, and valine and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a preservative. Examples of preservatives include, but are not limited to, acetone sodium bisulfite, alpha-tocopherol, benzalkonium chloride, benzyl alcohol, benzyl benzoate, benzyl chloride, boric acid, butylated hydroxyanisole, butylated hydroxytoluene, butylparaben, chlorobutanol, chlorobutanol hemihydrate, cresol, diethyl pyrocarbonate, edetate calcium disodium, edetate disodium, edetate sodium, edetic acid, hexylresorcinol, metacresol, methylparaben, miripirium chloride, monothioglycerol, nitrogen, phenol, phenylethyl alcohol, phenylmercuric nitrate, potassium bisulfite, potassium metabisulfite, propylparaben, sodium ascorbate, sodium benzoate, sodium bisulfate, sodium chlorate, sodium dithionite, sodium formaldehyde sulfoxylate, sodium iodide, sodium metabisulfite, sodium sulfite, sodium tartrate, sulfur dioxide, sulfurous acid, and thimerosal and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a salt formation agent. Examples of salt formation agents include, but are not limited to, acetic acid, acetic anhydride, adipic acid, ammonium acetate, ammonium sulfate, anhydrous citric acid, benzoic acid, calcium chloride, calcium gluceptate, calcium hydroxide, calcium, carbon dioxide, citric acid monohydrate, dibasic potassium phosphate, diethanolamine, disodium citrate sesquihydrate, disodium hydrogen citrate, hydrochloric acid, isoleucine, lactic acid (dl), lactobionic acid, magnesium chloride, magnesium stearate, maleic acid, metaphosphoric acid, methanesulfonic acid, nitric acid, phosphate ion, phosphoric acid, sodium hydroxide, sodium hypochlorite, sodium phosphate dihydrate, sodium phosphate, sodium phosphate p-32, sodium phosphate dibasic dihydrate, sodium phosphate dibasic dodecahydrate, sodium phosphate dibasic, sodium phosphate dibasic (anhydrous), sodium phosphate dibasic heptahydrate, sodium phosphate monobasic (anhydrous), sodium phosphate monobasic dihydrate, sodium phosphate monobasic monohydrate, sodium phosphate monobasic, and trifluoroacetic acid and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a chelator or chelating agent. Examples of chelators or chelating agents include, but are not limited to, caldiamide sodium, caloxetate trisodium, calteridol calcium, edetate calcium disodium, edetate disodium, edetate sodium, edetic acid, ferric chloride, gluceptate sodium, methylboronic acid, nioxime, oxidronate disodium, peg-60 hydrogenated castor oil, pentasodium pentetate, pentetate calcium trisodium, pentetic acid, sodium phosphite, sodium pyrophosphate, sodium succinate hexahydrate, sodium trimetaphosphate, succimer, and versetamide and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a viscosity enhancer. Examples of viscosity enhancers include, but are not limited to, carboxymethylcellulose, carboxymethylcellulose sodium, croscarmellose sodium, crospovidone, ethylene-vinyl acetate copolymer (15% vinyl acetate), gelatin, hetastarch, human albumin microspheres, hyaluronate sodium, hypromellose, methylcellulose, methylpyrrolidone, microcrystalline cellulose, polyvinyl alcohol, povidone K12, povidone K17, povidone, starch, and trimethylsilyl treated dimethiconol/trimethylsiloxysilicate crosspolymer and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a contrast agent. Examples of contrast agents include, but are not limited to, diatrizoic acid, perflutren, stannous chloride, stannous fluoride, stannous tartrate, tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate, and tetrofosmin and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain an anti-foam agent. Examples of anti-foam agents include, but are not limited to, dimethicone, polysiloxane, silicone, and simethicone and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a control release agent. Examples of control release agents include, but are not limited to, poly(dl-lactic-co-glycolic acid), (50:50; 12000 mw), polyglactin, and polylactide and combinations thereof. In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a lubricant. Examples of lubricants include, but are not limited to, silicone and simethicone and combinations thereof.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain an adhesive. An example of an adhesive includes, but is not limited to, Duro-Tak 87-2287.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain an analgesic. An example of an analgesic includes, but is not limited to, disodium sulfosalicylate.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain an anti-heparin agent. An example of an anti-heparin agent includes, but is not limited to, protamine sulfate.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain an antiviral agent. An example of an antiviral agent includes, but is not limited to, tromantadine.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a colorant. An example of a colorant includes, but is not limited to, methylene blue.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain an emollient. An example of an emollient includes, but is not limited to, urethane.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein contain a propellant. An example of a propellant includes, but is not limited to, dichlorodifluoromethane.

The formulations prepared by the process provided herein are single-dose, ready-to-use pharmaceutical formulations packaged in a container for parenteral administration (injection or infusion). For example, the pharmaceutical formulation is prepared to contain the therapeutically effective amount of the compound of Formula (I), including amorphous and polymorph forms thereof, and is intended to be used in a single subject for a single fusion or injection. The formulations provided herein are not designed for multiple-dose administration or for multiple use. The formulations provided herein are “ready-to-use,” i.e., formulations that do not require constitution or dilution with a prescribed amount of diluent, e.g., water for injection or other suitable diluent, before use by the designated route. For example, a formulation in a vial, of the desired concentration, that only needs to be drawn up into a syringe.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises a volume of about 0.1 mL to about 10 mL per container (i.e., per injection). For example, about 0.1 mL to about 10 mL, about 0.1 mL to about 5 mL, about 0.1 mL to about 4 mL, about 0.1 mL to about 3 mL, about 0.1 mL to about 2 mL, about 0.1 mL to about 1 mL, about 0.1 mL to about 0.5 mL, about 0.1 mL to about 0.25 mL, about 2 mL to about 10 mL, about 2 mL to about 5 mL, about 2 mL to about 4 mL, about 2 mL to about 3 mL, about 3 mL to about 5 mL, about 3 mL to about 10 mL, about 0.5 mL to about 1 mL, about 0.25 mL to about 2 mL. In some embodiments, the single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises a volume of about 1 mL to about 10 mL per container (i.e., per injection). For example, about 1 mL to about 10 mL, about 1 mL to about 5 mL, about 1 mL to about 4 mL, about 1 mL to about 3 mL, about 1 mL to about 2 mL, about 2 mL to about 10 mL, about 2 mL to about 5 mL, about 2 mL to about 4 mL, about 2 mL to about 3 mL, about 3 mL to about 5 mL, about 3 mL to about 10 mL. In some embodiments, the formulation comprises a volume of about 2 mL per container (i.e., injection).

In some embodiments, the unit dosage of the compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.1 μg/kg to about 10 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.1 μg/kg to about 5 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.2 μg/kg to about 9 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.25 μg/kg to about 8 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.3 μg/kg to about 7 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.4 μg/kg to about 6 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.5 μg/kg to about 5 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 0.6 μg/kg to about 5 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 1.0 μg/kg to about 4 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 2.0 μg/kg to about 4 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 3.0 μg/kg to about 5 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 4.0 μg/kg to about 6 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is about 5.0 μg/kg to about 10 μg/kg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.001 mg to 1 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.001 mg to 0.5 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.001 mg to 0.3 mg in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.01 mg to 1 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.01 mg to 0.5 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.01 mg to 0.3 mg in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.03 mg to 0.9 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.03 mg to 0.23 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.05 mg to 0.8 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.07 mg to 0.7 mg of body weight in humans.

In some embodiments, the unit dosage of compounds of Formula (I), including amorphous and polymorph forms thereof, is 0.08 mg to 0.7 mg of body weight in humans. In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.1 mg to 0.6 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.12 mg to 0.6 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.14 mg to 0.5 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.16 mg to 0.5 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.18 mg to 0.4 mg of body weight in humans.

In some embodiments, the unit dosage of compound of Formula (I), including amorphous and polymorph forms thereof, is 0.2 mg to 0.4 mg of body weight in humans.

In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein are stable for at least 3 months. For example, the formulations do not exhibit a change (e.g., greater than 5%) in one or more of polymorph forms (e.g., an increase or decrease of a certain form), appearance, pH, percent impurities, activity (as measured by in vitro assays), or osmolarity over time, e.g., at least 3 months as compared to the original formulation after manufacturing. In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein are stable for at least 6 months. For example, the formulations do not exhibit a significant change (e.g., greater than 5%) in one or more of polymorph form (e.g., an increase or decrease of a certain form), appearance, pH, percent impurities, activity (as measured by in vitro assays), or osmolarity over time, e.g., at least 6 months as compared to the original formulation after manufacturing. In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein are stable for at least 9 months. For example, the formulations do not exhibit a significant change (e.g., greater than 5%) in one or more of polymorph form (e.g., an increase or decrease of a certain form), appearance, pH, percent impurities, activity (as measured by in vitro assays), or osmolarity over time, e.g., at least 9 months as compared to the original formulation after manufacturing. In some embodiments, the single-dose, ready-to-use pharmaceutical formulations prepared by the process provided herein are stable for at least 12 months. For example, the formulations do not exhibit a significant change, as defined by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), in one or more of polymorph form (e.g., an increase or decrease of a certain form), appearance, pH, percent impurities, activity (as measured by in vitro assays), or osmolarity over time, e.g., at least 12 months as compared to the original formulation after manufacturing.

In some such embodiments, the single-dose, ready-to-use pharmaceutical formulation prepared by the process provided herein comprises between about 0.005 mg/mL and 2.5 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof, for example, between about 0.005 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 1.8 mg/mL, about 0.025 mg/mL to about 1.6 mg/mL, about 0.05 mg/mL to about 1.5 mg/mL, about 0.075 mg/mL to about 1.25 mg/mL, about 0.1 mg/mL to about 1 mg/mL, or about 0.25 mg/mL to about 0.75 mg/mL. In some such embodiments, the pharmaceutical formulation comprises about 0.015 mg/mL to about 0.115 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof. In some such embodiments, the pharmaceutical formulation comprises about 0.015 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof. In some such embodiments, the pharmaceutical formulation comprises about 0.035 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof. In some such embodiments, the pharmaceutical formulation comprises about 0.115 mg/mL of the compound of Formula (I), including amorphous and polymorph forms thereof. In some embodiments, the injection volume comprises between about 0.1 mg/mL and 4 mg/mL. In some embodiments, the injection volume is 2 mg/mL.

The single-dose, ready-to-use formulations prepared by the process provided herein comprising a compound of Formula (I), including amorphous and polymorph forms thereof, can be formulated as a plurality of particles. For example, particles of a compound of Formula (I), including amorphous and polymorph forms thereof, can have a median particle size of less than 20 μm (e.g., less than about 15 μm; less than about 10 μm; less than about 7.5 μm; less than about 5 μm; less than about 2.5 μm; less than about 1 μm; and less than about 0.5 μm). For example, the median particle size can be between about 0.1 μm and 20 μm, such as between about 0.5-20, 0.5-15, 0.5-10, 0.5-7.5, 0.5-5, 0.5-2.5, 0.5-1, 2.5-15, 5-10, 7.5-20, or 1-5 μm. In some embodiments, the particles also comprise a polymer. Examples of suitable polymers include biocompatible and biodegradable polymers like poly(lactic acid), a poly(glycolic acid), a poly(lactic-co-glycolic acid), a poly(lactide-co-glycolide), and mixtures thereof. In some embodiments, the particles comprise poly(lactic-co-glycolic acid) (PLGA).

In some embodiments, the compound of Formula (I), including amorphous and polymorph forms thereof, e.g., a polymorph form of Formula (I), e.g., Form 1, has a particle size distribution (D value), e.g., a D50, of between about 1 and about 6 μm, such as between about 1.5 and about 5 μm, or about 2.4 to about 2.55 μm. For example, the D50 can be about 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 4, 4.5, or 5 μm. In some embodiments, the D50 value is about 2.55 μm. In some embodiments, the D50 value is about 2.45 μm. In some embodiments, the D50 value is about 2.1 μm. In some embodiments, the D50 value is about 2 μm. In some embodiments, the D50 value is about 1.6 μm. The D50 can be measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, laser diffraction and disc centrifugation.

In some embodiments, the single-dose, ready-to-use formulations prepared by the process provided herein comprising a compound of Formula (I), including amorphous and polymorph forms thereof, are administered parenterally, including intramuscularly, intra-articularly, periarticularly, intraspinally, intradiscal, intrasynovially, and epidurally. In some embodiments, the formulation is administered to a patient with disc degeneration. In some embodiments, the formulation is administered to a patient with osteoarthritis. In some embodiments, the formulation can be a bursa injection, a caudal injection (e.g., a caudal epidural steroid injection (ESI)), a facet injection, a facet synovial injection, a hip joint injection, an intradiscal injection, an occipital nerve injection, a sciatic/piriformis injection, a sacroiliac (SI) joint injection, or combinations thereof. In some embodiments, the formulation can be injected locally, for example, in a patient with osteoarthritis, at the site of osteoarthritis (e.g., knee, hip, shoulder, etc.). Injections can occur at one or more locations surrounding the joint. In some embodiments, the injection is guided using an imaging method such as ultrasound. In some embodiments, administration (e.g., injection) of the formulation is preceded or combined with a local anesthetic.

The single-dose, ready-to-use formulations prepared by the process provided herein comprising a compound of Formula (I), including amorphous and polymorph forms thereof, can also be administered in combination (administered together or sequentially) with other known agents.

In some embodiments, the single-dose, ready-to-use formulations prepared by the process provided herein comprising a compound of Formula (I), including amorphous and polymorph forms thereof, can be administered in combination with one or more of the following: (a) Nonsteroidal anti-inflammatory drugs (NSAIDs), including, but not limited to, ibuprofen, naproxen, aspirin, acetaminophen, indomethacin (e.g., INDOCIN® and TIVORBEX®), diclofenac by mouth or to the affected area (e.g., VOLTAREN®, ZIPSOR®, PENNSAID®, FLECTOR®, and CATAFLAM®), meloxicam (e.g., MOBIC®), celecoxib (e.g., CELEBREX®), piroxicam (e.g., FELDENE®), etodolac (e.g., LODINE®), nabumetone (e.g., RELAFEN®), lumiracoxib, valdecoxib (e.g., BEXTRA®), etoricoxib, parecoxib, fenoprofen (e.g., NALFON®), oxaprozin (e.g., DAYPRO®), mefanamic acid (e.g. PONSTEL®), diflunisal (e.g., DOLOBID®), fenoprofen (e.g., NALFON®), flurbirofen (e.g., ANSAID®), ketoprofen (e.g., ORUVAIL®), ketorolac (e.g.,) TORADOL®, sulindac (e.g., CLINORIL®), meclofenamate, choline salicylate-magnesium salicylate, salsalate (e.g., DISALCID®), and tolmetin (e.g., TOLECTIN®); (b) physical therapy; (c) injections of corticosteroid medications such as, e.g., prednisone, dexamethasone, hydrocortisone, and methylprenisolone; (d) injections of hyaluronic acid derivatives (e.g., HYALGAN®, SYNVISC®, EUFLEXXA®, GEL-ONE®, MONOVISC®, ORTHOVISC®, and SUPARTZ®); (e) injections or topical application of Capsaicin (e.g., CAPSAGEL®); (f) narcotics, such as, e.g., codeine, fentanyl, hydrocodone, hydromorphone, morphine, meperidine, oxycodone, and tramadol (e.g., UILTRAM®, CONZIP®, and RYZOLT®); (g) antidepressants such as dulozetine (e.g., CYMBALTA®); (h) braces and/or shoe inserts or any device that can immobilize or support the joints to help keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices); (i) realigning bones (osteotomy); (j) joint replacement (arthroplasty); and (k) chronic pain class.

In some embodiments, the single-dose, ready-to-use formulations prepared by the process provided herein comprising a compound of Formula (I), including amorphous and polymorph forms thereof, can be used to treat osteoarthritis. In some embodiments, the formulations can be used to treat osteoarthritis in combination with one or more of the following drugs or methods: prednisone, methylprednisolone, SYNVISC® (hylan G-F 20), ABT-981 [MAbs (2015) 7(3):605-619], stem cell injection, JNJ-42160443 (fulranumab), platelet rich plasma (PRGF) injection, tanezumab, venlafaxine, PH-797804, PG-530742 (the dihydrated sodium salt PG-116800), Sprifermin (AS902330, rhFGF-18), epicutaneous ketoprofen in transfersome (IDEA-033) [Annals of the Rheumatic Diseases (2007) 66(9):1178-1183], FX005 and FX006 (both by Flexion Therapeutics, Inc.), JNJ-39439335 (Mavatrep) [J. Med. Chem. (2015) 58(9):3859-3874], polmacoxib (Acelex, CG100649), balicatib (AAE581), GSK3196165, cebranopadol (GRT6005), fasinumab (REGN475), TPX-100 (by OrthoTrophix), PRX167700 (by Proximagen), EP 104IAR (extended release fluticasone propionate composition), LY2951742 and LY545694 (both by Eli Lilly & Co), Adalimumab (Humira®), GW842166 (by GSK), YY1201 (by Yooyoung Pharmaceutical Co., Ltd.), CF101 (IB-MECA) and CF602 (both by Can-Fite BioPharma), PLA-695 (by Pfizer), VX-150 (by Vertex), ADL5859 and ADL5747 (both by Adolor Corporation now Cubist Pharmaceuticals), funapide (INN) (TV-45070, XEN402), AGG-523 (by Pfizer) [Osteoarthritis Cartilage (2011) 19(3):315-323], CNTX-4975 (capsaicin for injection by Centrexion Corporation), CR845 (by Cara Therapeutics), ASP7962 (by Astellas Pharma), DA-5202 (by Dong-A ST Co., Ltd.), GZ389988 (by Sanofi-Genzyme), and MEDI 7352 (by AstraZeneca), LNA043 (by Novartis).

4. Kits

Also provided herein are kits. Typically, a kit includes one or more formulations as described herein, e.g., a single-dose, ready-to-use formulation prepared by the process provided herein comprising a compound of Formula (I), including amorphous and polymorph forms thereof. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering the formulation as provided herein, and directions for use of the kit (e.g., instructions for treating a patient). In some embodiments, the kit can include a formulation as described herein and a label that indicates that the contents are to be administered to a patient with bone or cartilage diseases or osteoarthritis. The actual dose of the compound of Formula (I) provided herein depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

5. Methods for Treating Osteoarthritis

Provided are methods for the treatment of osteoarthritis in a subject. The methods comprise administering to the subject a therapeutically effective amount of a single-dose, ready-to-use formulation provided herein comprising a compound of Formula (I), including salt and amorphous or polymorph forms thereof. In some embodiments, the formulation is prepared by the process provided herein. In some embodiments, the methods provided herein include intra-articular administration of a single-dose, ready-to-use pharmaceutical formulation comprising a therapeutically effective amount of a compound of Formula (I), including salt and amorphous and polymorph forms thereof. In some embodiments, the methods provided herein include intra-articular administration of a single-dose, ready-to-use pharmaceutical formulation prepared by a process provided herein. In some embodiments, the polymorph form is Form 1. In some embodiments, the polymorph form is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water.

In some embodiments, provided herein are methods for treating osteoarthritis in a subject comprising intra-articular administration to the subject a single-dose, ready-to-use pharmaceutical formulation comprising a therapeutically effective amount of a compound of Formula (I). In some embodiments, the compound of Formula (I) in the formulation comprises Form 1. In some embodiments, the compound of Formula (I) in the formulation comprises a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the compound of Formula (I) in the formulation is substantially present as a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and 20% by weight water.

In some embodiments of the method provided herein, the single-dose, ready-to-use formulations prepared by the process provided herein comprising a compound of Formula (I), including amorphous and polymorph forms thereof, are administered parenterally, including intramuscularly, intra-articularly, periarticularly, intradiscal, intraspinally, intrasynovially, and epidurally. In some embodiments, the formulation is administered to a patient with disc degeneration. In some embodiments, the formulation is administered to a patient with osteoarthritis. In some embodiments, the formulation can be a bursa injection, a caudal injection (e.g., a caudal epidural steroid injection (ESI)), a facet injection, a facet synovial injection, a hip joint injection, an intradiscal injection, an occipital nerve injection, a sciatic/piriformis injection, a sacroiliac (SI) joint injection, or combinations thereof. In some embodiments, the formulation can be injected locally, for example, in a patient with osteoarthritis, at the site of osteoarthritis (e.g., knee, hip, shoulder, etc.). Injections can occur at one or more locations surrounding the joint. In some embodiments, the formulation is administered intra-articularly. In some embodiments, the injection is guided using an imaging method such as ultrasound. In some embodiments, administration (e.g., injection) of the formulation is preceded or combined with a local anesthetic.

In some embodiments of the methods provided herein, the formulation comprising a compound of Formula (I), including salt and amorphous and polymorph forms thereof, is administered once. In some embodiments, the formulation comprising a compound of Formula (I), including salt and amorphous and polymorph forms thereof, is administered more than once. For example, the formulation is administered by injections spaced at least 7 days apart. In some embodiments, the formulation is administered once every two weeks. In some embodiments, the formulation is administered once every three weeks. In some embodiments, the formulation is administered once every four weeks. In some embodiments, the formulation is administered once every six weeks. In some embodiments, the formulation is administered once every eight weeks. In some embodiments, the formulation is administered once every twelve weeks (three months).

6. Polymorphs

Provided herein are formulations comprising a compound of Formula (I):

including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

The compound of Formula (I) provided herein can be prepared using methods known and understood by those of ordinary skill in the art. For example, synthetic methods such as those described in PCT/US2013/031055 can be used, and this application is herein incorporated by reference in its entirety.

The formulations provided herein can contain a polymorph form of the compound of Formula (I). The forms include, e.g., solvates, hydrates, non-stoichiometric or stoichiometric hydrates, and non-solvated forms of the compound of Formula (I), including, for example, polymorph Forms 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 13.

One such polymorph is a polymorph known as Form 1. Form 1 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, Form 1 has an X-ray powder diffraction (XRPD or XRD) pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2. In some embodiments, Form 1 has an XRPD pattern with at least peaks at °2θ values of 6.8±0.2, 12.4±0.2, 16.5±0.2, 18.5±0.2, and 19.2±0.2. In some embodiments, Form 1 has an XRPD pattern with at least peaks at °2θ values of 6.8±0.2, 9.3±0.2, 12.4±0.2, 13.9±0.2, 16.5±0.2, 18.5±0.2, 19.2±0.2, and 24.6±0.2. For example, in some embodiments, Form 1 has an XRPD pattern with at least peaks at °2θ values of 6.8±0.2, 9.3±0.2, 12.4±0.2, 13.9±0.2, 14.5±0.2, 16.5±0.2, 18.5±0.2, 19.2±0.2, 20.3±0.2, and 24.6±0.2.

In some embodiments, the formulations provided herein comprise a composition comprising polymorph Form 1. In some embodiments, the composition can be substantially pure. For example, the composition has a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than about 15% by weight of other forms of the compound of Formula (I). For example, the composition can contain less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than about 15% by weight of the polymorph Form 9. For example, the composition can contain less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of the polymorph of Form 9. In some embodiments, the composition contains less than about 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, and Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water, or a combination of two or more thereof.

In some embodiments, provided herein is a formulation comprising polymorph Form 1 that exhibits an endotherm between about 50-100° C. as measured by differential scanning calorimetry (DSC) related to sorbed water. In some embodiments, polymorph Form 1 exhibits a recrystallization event that is observed between about 270-290° C., e.g., around 280° C. In some embodiments, the endotherm and exotherm are observed when using a scan rate of 10° C. per minute.

In some embodiments, provided herein is a formulation comprising polymorph Form 1 that recrystallizes into Form 9 with a melting point of around 363° C. In some embodiments, polymorph Form 1 undergoes a total mass loss of about 0.33% before around 100° C., e.g., from about 39° C. to about 100° C., as measured by thermal gravimetric analysis (TGA).

In some embodiments, polymorph Form 1 is prepared by a method comprising drying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, to generate polymorph Form 1. In some embodiments, the composition comprises a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, polymorph Form 1 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate polymorph Form 1 as a residual solid. In some embodiments, the reslurrying takes place at room temperature (RT). In some embodiments, the reslurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 1 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof in a solvent or mixture of solvents to generate polymorph Form 1 as a residual solid. In some embodiments, the compound of Formula (I) is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the solvent is methanol. In some embodiments, the solvent is toluene. In some embodiments, the solvent is heptane. In some embodiments, the solvent is dichloromethane (DCM). In some embodiments, the solvent is water. In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and acetonitrile, methanol, ethyl acetate (EA), methyl tert-butyl ether (MtBE), isopropyl alcohol (IPAc), methyl acetate (MA), methyl isobutyl ketone (MIBK), DCM, n-butyl acetate, heptane, toluene, or n-butanol. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at room temperature. In some embodiments, the reslurrying takes place at around 50° C. In some embodiments, polymorph Form 1 is prepared by a method further comprising drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

Provided herein are formulations comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, for example, above 30% relative humidity (RH), Form 1 readily sorbs water and shows a distinctive shift in Form 1 peaks from 6.8±0.2 to 6.2±0.2 and 12.6±0.2 to 11±0.2. In some embodiments, a non-stoichiometric or stoichiometric hydrate of Form 1 comprises up to about 20% by weight water. For example, up to about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or greater than 1% water by weight. In some embodiments, a non-stoichiometric or stoichiometric hydrate of Form 1 has between 1 to about 20% water by weight, e.g., between 1% and about 10%, about 5% and about 15%, about 10% and about 20%, 1% and about 5%, about 5% and about 10%, about 10% and about 15%, about 15% and about 20%, or about 17% and about 20% water by weight.

In some embodiments, provided herein is a formulation comprising a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I) (e.g., anhydrous forms of the compound of Formula (I)). In some embodiments, the composition contains less than 20% by weight of polymorph Form 9 having X-ray powder diffraction pattern comprising peaks at °2θ values of 4.9±0.2, 18.6±0.2, and 21.1±0.2. For example, the composition contains less than 15% by weight of Form 9, such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Form 9. In some embodiments, the composition contains less than 15% of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11, or a combination of two or more thereof.

Another example of a non-stoichiometric hydrate of polymorph Form 1 is referred to as Form 12.

In one embodiment, provided herein is a formulation comprising polymorph Form 12. In some embodiments, Form 12 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ positions 6.4±0.2, 11.0±0.2, and 18.4±0.2. In some embodiments, Form 12 has an XRPD pattern with at least peaks at °20 positions 6.4±0.2, 9.2±0.2, 11.0±0.2, 18.4±0.2, and 19.7±0.2. In some embodiments, Form 12 has an XRPD pattern with at least peaks at °20 positions 6.4±0.2, 9.2±0.2, 11.0±0.2, 15.6±0.2, 18.4±0.2, 19.7±0.2, 24.4±0.2, and 25.2±0.2. For example, in some embodiments, Form 12 has an XRPD pattern with at least peaks at °20 positions 6.4±0.2, 9.2±0.2, 11.0±0.2, 15.6±0.2, 16.1±0.2, 18.4±0.2, 19.7±0.2, 20.8±0.2, 24.4±0.2, and 25.2±0.2.

In some embodiments, provided herein is polymorph Form 12 that exhibits an endotherm between about 50-100° C. as measured by DSC. In some embodiments, polymorph Form 12 exhibits an exotherm at around 283° C. In some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, provided herein is polymorph Form 12 that has a melting point of around 364° C. In some embodiments, polymorph Form 12 undergoes a weight loss of about 1.4% before around 100° C., e.g., from about 30° C. to about 100° C., as measured by TGA.

One example of a non-stoichiometric hydrate of polymorph Form 1 is referred to as Form 13.

In one embodiment, provided herein is a formulation comprising polymorph Form 13. In some embodiments, polymorph Form 13 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2. In some embodiments, Form 13 has an XRPD pattern with at least peaks at °2θ values of 6.8±0.2, 12.4±0.2, 16.5±0.2, 18.5±0.2, and 19.2±0.2. In some embodiments, Form 13 has an XRPD pattern with at least peaks at °2θ values of 6.8±0.2, 9.3±0.2, 12.4±0.2, 13.9±0.2, 16.5±0.2, 18.5±0.2, 19.2±0.2, and 24.6±0.2. For example, in some embodiments, Form 13 has an XRPD pattern with at least peaks at °2θ values of 6.8±0.2, 9.3±0.2, 12.4±0.2, 13.9±0.2, 14.5±0.2, 16.5±0.2, 18.5±0.2, 19.2±0.2, 20.3±0.2, and 24.6±0.2.

In some embodiments, polymorph Form 13 exhibits an endotherm between about 50-100° C. as measured by DSC. In some embodiments, polymorph Form 13 exhibits an exotherm at between about 265-285° C., e.g., around 278° C. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 13 has a melting point of around 363° C. In some embodiments, polymorph Form 13 undergoes a weight loss of about 1.9% before around 100° C. as measured by TGA.

Provided herein are methods of preparing a non-stoichiometric or stoichiometric hydrate of polymorph Form 1. In some embodiments, the method comprises reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate a non-stoichiometric or stoichiometric hydrate of polymorph Form 1 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) is a mixture of a non-stoichiometric or stoichiometric hydrate of polymorph Form 1 and Form 1. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, the method comprises reslurrying a composition comprising a mixture of a non-stoichiometric or stoichiometric hydrate of polymorph Form 1 and Form 1 in a solvent or mixture of solvents to generate a non-stoichiometric or stoichiometric hydrate of polymorph Form 1 as a residual solid. In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and acetonitrile, methanol, MtBE, MA, MIBK, DCM, IPAc, n-butyl acetate, heptane, toluene, or n-butanol. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 2. Form 2 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 2 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 7.0±0.2, 21.5±0.2, and 22.0±0.2. In some embodiments, Form 2 has an XRPD pattern with at least peaks at °2θ values of 7.0±0.2, 18.9±0.2, 21.5±0.2, 22.0±0.2, and 24.2±0.2. In some embodiments, Form 2 has an XRPD pattern with at least peaks at °2θ values of 7.0±0.2, 14.1±0.2, 18.9±0.2, 19.2±0.2, 21.5±0.2, 22.0±0.2, 24.2±0.2, and 26.4±0.2. For example, in some embodiments, Form 2 has an XRPD pattern with at least peaks at °2θ values of 7.0±0.2, 10.4±0.2, 14.1±0.2, 17.6±0.2, 18.9±0.2, 19.2±0.2, 21.5±0.2, 22.0±0.2, 24.2±0.2, and 26.4±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 2. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 2 exhibits an endotherm between about 50-100° C. as measured by DSC. In some embodiments, polymorph Form 2 exhibits an endotherm between about 220-230° C. In some embodiments, polymorph Form 2 exhibits an exotherm between about 233-238° C. In some embodiments, polymorph Form 2 exhibits an exotherm between about 290-295° C. In some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 2 has a melting point of around 363° C. In some embodiments, polymorph Form 2 undergoes a weight loss of about 2.7% before around 116° C., e.g., from about 36° C. to about 116° C., as measured by TGA.

In some embodiments, polymorph Form 2 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 2 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) comprises a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 2 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 2 as a residual solid. In some embodiments, the solvent is acetonitrile. In some embodiments, the solvent is ethanol. In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and ethanol or water and n-propanol. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 3. Form 3 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 3 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 7.2±0.2, 22.2±0.2, and 24.4±0.2. In some embodiments, Form 3 has an XRPD pattern with at least peaks at °2θ values of 6.3±0.2, 7.2±0.2, 21.6±0.2, 22.2±0.2, and 24.4±0.2. In some embodiments, Form 3 has an XRPD pattern with at least peaks at °2θ values of 6.3±0.2, 7.2±0.2, 11.0±0.2, 18.4±0.2, 19.0±0.2, 21.6±0.2, 22.2±0.2, and 24.4±0.2. For example, in some embodiments, Form 3 has an XRPD pattern with at least peaks at °2θ values of 6.3±0.2, 7.2±0.2, 11.0±0.2, 14.2±0.2, 17.8±0.2, 18.4±0.2, 19.0±0.2, 21.6±0.2, 22.2±0.2, and 24.4±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 3. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 3 exhibits an exotherm between about 190-220° C., as measured by DSC. In some embodiments, polymorph Form 3 exhibits an exotherm at between about 225-235° C., e.g., around 230° C., as measured by DSC. In some embodiments, polymorph Form 3 exhibits an exotherm at between about 292-300° C., e.g., around 297° C., as measured by DSC. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 3 has a melting point of around 365° C. In some embodiments, polymorph Form 3 undergoes a weight loss of about 1.6% before around 81° C. and a weight loss of about 1.7% between about 81-169° C. as measured by TGA.

In some embodiments, polymorph Form 3 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 3 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) comprises a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 3 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 3 as a residual solid. In some embodiments, the solvent is IPAc. In some embodiments, the solvent is n-butyl acetate. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 4. Form 4 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 4 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 7.0±0.2, 21.8±0.2, and 25.1±0.2. In some embodiments, Form 4 has an XRPD pattern with at least peaks at °2θ values of 7.0±0.2, 19.5±0.2, 21.8±0.2, 23.2±0.2, and 25.1±0.2. In some embodiments, Form 4 has an XRPD pattern with at least peaks at °2θ values of 7.0±0.2, 17.6±0.2, 18.3±0.2, 19.5±0.2, 21.8±0.2, 23.2±0.2, 25.1±0.2, and 25.8±0.2. For example, in some embodiments, Form 4 has an XRPD pattern with at least peaks at °2θ values of 7.0±0.2, 9.6±0.2, 17.6±0.2, 18.3±0.2, 19.5±0.2, 21.8±0.2, 23.2±0.2, 25.1±0.2, 25.8±0.2, and 29.3±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 4. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 4 exhibits an endotherm between about 50-100° C. as measured by DSC. In some embodiments, polymorph Form 4 exhibits an endotherm at between about 180-215° C. In some embodiments, polymorph Form 4 exhibits an endotherm between about 220-230° C. In some embodiments, polymorph Form 4 exhibits an exotherm at between about 230-240° C., e.g., around 235° C. In some embodiments, polymorph Form 4 exhibits an exotherm at between about 300-310° C. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 4 has a melting point of between about 366-369° C., e.g., around 367° C. In some embodiments, polymorph Form 4 undergoes a weight loss of about 8.3% before around 200° C., e.g., from about 42° C. to about 200° C., as measured by TGA.

In some embodiments, polymorph Form 4 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 4 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) comprises a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 4 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 4 as a residual solid. In some embodiments, the solvent is EA. In some embodiments, the solvent is MA. In some embodiments, the solvent is MtBE. In some embodiments, the solvent is n-propanol. In some embodiments, the solvent is acetone. In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and MA, EA, or acetone. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 5. Form 5 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 5 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 7.3±0.2, 22.3±0.2, and 24.5±0.2. In some embodiments, Form 5 has an XRPD pattern with at least peaks at °2θ values of 6.3±0.2, 7.3±0.2, 21.7±0.2, 22.3±0.2, and 24.5±0.2. In some embodiments, Form 5 has an XRPD pattern with at least peaks at °2θ values of 6.3±0.2, 7.3±0.2, 11.0±0.2, 19.1±0.2, 19.5±0.2, 21.7±0.2, 22.3±0.2, and 24.5±0.2. For example, in some embodiments, Form 5 has an XRPD pattern with at least peaks at °2θ values of 6.3±0.2, 7.3±0.2, 11.0±0.2, 14.3±0.2, 19.1±0.2, 19.5±0.2, 21.7±0.2, 22.3±0.2, 24.5±0.2, and 26.5±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 5. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 5 exhibits an endotherm between about 50-100° C. as measured by DSC. In some embodiments, polymorph Form 5 exhibits an endotherm at between about 210-235° C., e.g., around 222° C. In some embodiments, polymorph Form 5 exhibits an exotherm at between about 227-240° C., e.g., around 235° C. In some embodiments, polymorph Form 5 exhibits an exotherm at between about 280-300° C., e.g., around 293° C. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 5 has a melting point of around 363° C. In some embodiments, polymorph Form 5 undergoes a weight loss of about 3.1% before around 100° C. and about 1.7% between about 100-250° C. as measured by TGA.

In some embodiments, polymorph Form 5 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 5 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) comprises a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 5 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 5 as a residual solid. In some embodiments, the solvent is MtBE. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 6. Form 6 is an anhydrous polymorph of the compound of Formula (I).

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 6. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 5, Form 7, Form 8, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 6 exhibits an exotherm between about 245-260° C. as measured by DSC. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute. In some embodiments, polymorph Form 6 has a melting point of around 364° C.

In some embodiments, polymorph Form 6 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 6 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 6 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 6 as a residual solid. In some embodiments, the solvent is IPAc. In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and IPAc. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 7. Form 7 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 7 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 7.1±0.2, 21.6±0.2, and 23.2±0.2. In some embodiments, Form 7 has an XRPD pattern with at least peaks at °2θ values of 4.9±0.2, 7.1±0.2, 18.5±0.2, 21.6±0.2, and 23.2±0.2. In some embodiments, Form 7 has an XRPD pattern with at least peaks at °2θ values of 4.9±0.2, 7.1±0.2, 10.9±0.2, 18.5±0.2, 19.4±0.2, 21.6±0.2, 23.2±0.2, and 30.3±0.2. For example, in some embodiments, Form 7 has an XRPD pattern with at least peaks at °2θ values of 4.9±0.2, 7.1±0.2, 8.8±0.2, 10.9±0.2, 18.5±0.2, 19.4±0.2, 21.6±0.2, 22.1±0.2, 23.2±0.2, and 30.3±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 7. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 8, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 7 exhibits an exotherm between about 227-235° C., e.g., around 232° C., as measured by DSC. In some embodiments, polymorph Form 7 exhibits an exotherm between about 299-305° C., e.g., around 303° C. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 7 has a melting point of around 365° C. In some embodiments, polymorph Form 7 undergoes a weight loss of about 12% before around 200° C., e.g., from about 36° C. to about 200° C., as measured by TGA.

In some embodiments, polymorph Form 7 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 7 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 7 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 7 as a residual solid. In some embodiments, the solvent is methyl ethyl ketone (MEK). In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and MEK. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 8. Form 8 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 8 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 6.9±0.2, 17.7±0.2, and 21.5±0.2. In some embodiments, Form 8 has an XRPD pattern with at least peaks at °2θ values of 6.9±0.2, 11.5±0.2, 17.7±0.2, 21.5±0.2, and 27.6±0.2. In some embodiments, Form 8 has an XRPD pattern with at least peaks at °2θ values of 6.9±0.2, 11.5±0.2, 15.3±0.2, 16.9±0.2, 17.7±0.2, 21.5±0.2, 27.6±0.2, and 28.9±0.2. For example, in some embodiments, Form 8 has an XRPD pattern with at least peaks at °2θ values of 6.9±0.2, 11.5±0.2, 12.7±0.2, 14.2±0.2, 15.3±0.2, 16.9±0.2, 17.7±0.2, 21.5±0.2, 27.6±0.2, and 28.9±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 8. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 9, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 8 exhibits an endotherm between about 41-60° C. as measured by DSC. In some embodiments, polymorph Form 8 exhibits an exotherm at between about 221-235° C., e.g., around 231° C. In some embodiments, polymorph Form 8 exhibits an endotherm between about 279-290° C., e.g., around 285° C. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 8 has a melting point of around 364° C. In some embodiments, polymorph Form 8 undergoes a weight loss of about 4.2% before around 190° C. and about 3.9% between about 190-261° C. as measured by TGA.

In some embodiments, polymorph Form 8 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 8 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 8 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 8 as a residual solid. In some embodiments, the solvent is MIBK. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 9. Form 9 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 9 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 4.9±0.2, 18.6±0.2, and 21.1±0.2. In some embodiments, Form 9 has an XRPD pattern with at least peaks at °2θ values of 4.9±0.2, 18.6±0.2, 21.1±0.2, 24.1±0.2, and 25.2±0.2. In some embodiments, Form 9 has an XRPD pattern with at least peaks at °2θ values of 4.9±0.2, 15.3±0.2, 16.5±0.2, 18.6±0.2, 21.1±0.2, 22.4±0.2, 24.1±0.2, and 25.2±0.2. For example, in some embodiments, Form 9 has an XRPD pattern with at least peaks at °2θ values of 4.9±0.2, 10.1±0.2, 15.3±0.2, 16.5±0.2, 18.6±0.2, 21.1±0.2, 22.4±0.2, 24.1±0.2, 25.2±0.2, and 28.6±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 9. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 10, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 9 exhibits a single melting endotherm at around 364° C. as measured by DSC. For example, in some embodiments, the endotherm is observed when using a scan rate of 10° C. per minute. In some embodiments, other polymorph forms provided herein, such as, e.g., Form 1 and Form 2, can convert to Form 9 when heated to just before melting (i.e., around 364° C.).

In some embodiments, polymorph Form 9 has a melting point of around 364° C. In some embodiments, polymorph Form 9 undergoes a weight loss of about 0.28% before around 100° C., e.g., from about 30.5° C. to about 100° C., as measured by TGA.

In some embodiments, polymorph Form 9 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 9 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 9 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 9 as a residual solid. In some embodiments, the solvent is n-butanol. In some embodiments, the solvent is IPAc. In some embodiments, the solvent is n-butyl acetate. In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and ethanol or water and n-propanol. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 10. Polymorph Form 10 is a polymorph of the compound of Formula (I) comprising DMSO. For example, DMSO is on the surface of the polymorph. In one embodiment, polymorph Form 10 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °20 values of 20.7±0.2, 21.7±0.2, and 24.2±0.2. In some embodiments, Form 10 has an XRPD pattern with at least peaks at °2θ values of 18.2±0.2, 19.0±0.2, 20.7±0.2, 21.7±0.2, and 24.2±0.2. In some embodiments, Form 10 has an XRPD pattern with at least peaks at °20 values of 17.8±0.2, 18.2±0.2, 19.0±0.2, 20.7±0.2, 21.7±0.2, 23.4±0.2, 24.2±0.2, and 27.9±0.2. For example, in some embodiments, Form 10 has an XRPD pattern with at least peaks at °2θ values of 6.7±0.2, 17.8±0.2, 18.2±0.2, 19.0±0.2, 19.9±0.2, 20.7±0.2, 21.7±0.2, 23.4±0.2, 24.2±0.2, and 27.9±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 10. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 11, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 10 exhibits an endotherm between about 212-237° C. as measured by DSC. In some embodiments, polymorph Form 10 exhibits an endotherm at between about 234-245° C., e.g., around 237° C. In some embodiments, polymorph Form 10 exhibits an exotherm between about 300-325° C., e.g., around 308° C. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 10 has a melting point of between about 364-372° C., such as, e.g., around 369° C. In some embodiments, polymorph Form 10 undergoes a weight loss of about 0.6% before around 100° C., a weight loss of about 3.8% between about 100-170° C., and a weight loss of about 7.1% between about 170-260° C. as measured by TGA.

In some embodiments, polymorph Form 10 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 10 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 10 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 10 as a residual solid. In some embodiments, the solvent is DMSO. In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and DMSO. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

Provided herein is a formulation comprising a polymorph known as Form 11. Form 11 is an anhydrous polymorph of the compound of Formula (I). In one embodiment, polymorph Form 11 has an XRPD pattern, obtained with CuKα1-radiation, with at least peaks at °2θ values of 6.4±0.2, 18.5±0.2, and 22.4±0.2. In some embodiments, Form 11 has an XRPD pattern with at least peaks at °2θ values of 6.4±0.2, 17.8±0.2, 18.5±0.2, 19.9±0.2, and 22.4±0.2. In some embodiments, Form 11 has an XRPD pattern with at least peaks at °2θ values of 6.4±0.2, 8.4±0.2, 17.8±0.2, 18.5±0.2, 19.9±0.2, 22.4±0.2, 24.5±0.2, and 26.8±0.2. For example, in some embodiments, Form 11 has an XRPD pattern with at least peaks at °2θ values of 6.4±0.2, 8.4±0.2, 17.8±0.2, 18.5±0.2, 19.9±0.2, 20.3±0.2, 22.4±0.2, 22.9±0.2, 24.5±0.2, and 26.8±0.2.

In some embodiments, provided herein is a formulation comprising a composition comprising polymorph Form 11. In some embodiments, the composition is substantially pure. For example, the composition can have a purity of at least about 90%. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. For example, the composition can have a purity of at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%. In some embodiments, the composition is substantially free of other forms of the compound of Formula (I). For example, in some embodiments, the composition is substantially free of other anhydrous forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of other forms of the compound of Formula (I). In some embodiments, the composition contains less than 15% by weight of one or more other forms of the compound of Formula (I), such as less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less by weight of one or more other forms of the compound of Formula (I). For example, the composition can contain less than about 15% of Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, a non-stoichiometric or stoichiometric hydrate of Form 1, or a combination of two or more thereof.

In some embodiments, polymorph Form 11 exhibits an endotherm between about 215-230° C. as measured by DSC. In some embodiments, polymorph Form 11 exhibits an exotherm at between about 230-240° C., e.g., around 235° C. In some embodiments, polymorph Form 11 exhibits an exotherm between about 300-315° C., e.g., around 310° C. For example, in some embodiments, the endotherms and exotherms are observed when using a scan rate of 10° C. per minute.

In some embodiments, polymorph Form 11 has a melting point of around 368° C. In some embodiments, polymorph Form 11 undergoes a weight loss of about 0.8% before around 100° C. and a weight loss of about 7.0% between about 100-249° C., as measured by TGA.

In some embodiments, polymorph Form 11 is prepared by a method comprising reslurrying a composition comprising the compound of Formula (I), including amorphous and polymorph forms thereof, in a solvent or mixture of solvents to generate Form 11 as a residual solid. In some embodiments, the composition comprising the compound of Formula (I) is a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. In some embodiments, the reslurrying takes place at RT. In some embodiments, the slurrying takes place at around 50° C. In some embodiments, the method further comprises drying the residual solid, for example, under vacuum. In some embodiments, the drying is at a temperature of between about 60° C. and 90° C., such as, e.g., around 75° C.

In some embodiments, polymorph Form 11 is prepared by a method comprising reslurrying a composition comprising a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water in a solvent or mixture of solvents to generate polymorph Form 11 as a residual solid. In some embodiments, the solvent is dimethylformamide (DMF). In some embodiments, the solvent is in a mixture with water, for example the solvent can be a mixture of water and DMF. In some embodiments, the water is present in an amount of about 5% by weight. In some embodiments, the reslurrying takes place at RT. In some embodiments, the reslurrying takes place at around 50° C.

EXAMPLES Example 1: Preparation of Single-Dose, Ready-to-Use Formulations

Single-dose, ready-to-use formulations containing either 0.015 mg/mL, 0.025 mg/mL or 0.115 mg/mL of polymorph Form 1 of the compound of Formula (I) were prepared. The compound of Formula (I) was prepared according to the process provided in US 2013/0267495, incorporated herein by reference in its entirety. The polymorph of Form 1 was prepared as described herein.

For a 0.015 mg/mL Formulation:

Water, sodium carboxymethylcellulose (CMC) (5.55 g/kg), polysorbate 80 (0.50 g/kg), sodium phosphate monobasic monohydrate (0.268 g/kg), sodium phosphate dibasic heptahydrate (2.44 g/kg), and sodium chloride (9.11 g/kg) were added to a 300 L first tank. The aqueous solution in the first tank was then filtered through a 0.2 μm polyethersulfone (PES) filter into a second tank, where it was bulk sterilized. 0.15 g/kg of polymorph Form 1 of the compound of Formula (I), water for injection, and 0.5 g/kg polysorbate 80 were added to a 30 L third tank to form a slurry containing 15 μg/mL of the compound of Formula (I). The slurry was sterilized by overhead steam pressure, then added to the second tank containing the aqueous solution. The slurry was homogenized at 30 Hz and manufactured using principles of overkill cycle (F₀ ≥30). The mixture was aseptically mixed with sterile diluent to form a suspension with a concentration of 0.015 mg/mL of the compound of Formula (I). The bulk solution temperature was maintained at 250° F. as monitored by bottom TC and overhead pressure was maintained greater than the steam pressure introduced in the tank jacket (˜5 psi). To maintain overhead pressure during bleeding of the top valve next to the mixer to monitor TC above the tank, steam was introduced via the air filter into the tank to maintain pressure and high temperature. The steam pressure was monitored and bulk sterilization performed. The suspension was then aseptically filled using a Weiler 624 BFS machine into 3 mL polypropylene vials, with a target volume of 2.5 mL and a final concentration of 0.015 mg/mL of the compound of Formula (I). Each vial contained 0.03 mg of Form 1 of the compound of Formula (I) in 2 mL phosphate buffered saline. The vials were labeled and packaged.

For a 0.035 mg/mL Formulation:

Water, sodium carboxymethylcellulose (CMC) (5.55 g/kg), polysorbate 80 (0.50 g/kg), sodium phosphate monobasic monohydrate (0.268 g/kg), sodium phosphate dibasic heptahydrate (2.44 g/kg), and sodium chloride (9.11 g/kg) were added to a 300 L first tank. The aqueous solution in the first tank was then filtered through a 0.2 μm polyethersulfone (PES) filter into a second tank, where it was bulk sterilized. 0.35 g/kg of polymorph Form 1 of the compound of Formula (I), water for injection, and 0.5 g/kg polysorbate 80 were added to a 30 L third tank to form a slurry containing 35 μg/mL of the compound of Formula (I). The slurry was sterilized by overhead steam pressure, then added to the second tank containing the aqueous solution. The slurry was homogenized at 30 Hz and manufactured using principles of overkill cycle (F₀ ≥30). The mixture was aseptically mixed with sterile diluent to form a suspension with a concentration of 0.035 mg/mL of the compound of Formula (I). The bulk solution temperature was maintained at 250° F. as monitored by bottom TC and overhead pressure was maintained greater than the steam pressure introduced in the tank jacket (˜>5 psi). To maintain overhead pressure during bleeding of the top valve next to the mixer to monitor TC above the tank, steam was introduced via the air filter into the tank to maintain pressure and high temperature. The steam pressure was monitored and bulk sterilization performed. The suspension was then aseptically filled using a Weiler 624 BFS machine into 3 mL polypropylene vials, with a target volume of 2.5 mL and a final concentration of 0.035 mg/mL of the compound of Formula (I). Each vial contained 0.07 mg of Form 1 of the compound of Formula (I) in 2 mL phosphate buffered saline. The vials were labeled and packaged.

For a 0.075 mg/mL Formulation:

Water, sodium carboxymethylcellulose (CMC) (5.55 g/kg), polysorbate 80 (0.50 g/kg), sodium phosphate monobasic monohydrate (0.268 g/kg), sodium phosphate dibasic heptahydrate (2.44 g/kg), and sodium chloride (9.11 g/kg) were added to a 300 L first tank. The aqueous solution in the first tank was then filtered through a 0.2 μm polyethersulfone (PES) filter into a second tank, where it was bulk sterilized. 0.75 g/kg of polymorph Form 1 of the compound of Formula (I), water for injection, and 0.5 g/kg polysorbate 80 were added to a 30 L third tank to form a slurry containing 75 μg/mL of the compound of Formula (I). The slurry was sterilized by overhead steam pressure, then added to the second tank containing the aqueous solution. The slurry was homogenized at 30 Hz and manufactured using principles of overkill cycle (F₀ ≥30). The mixture was aseptically mixed with sterile diluent to form a suspension with a concentration of 0.075 mg/mL of the compound of Formula (I). The bulk solution temperature was maintained at 250° F. as monitored by bottom TC and overhead pressure was maintained greater than the steam pressure introduced in the tank jacket (˜>5 psi). To maintain overhead pressure during bleeding of the top valve next to the mixer to monitor TC above the tank, steam was introduced via the air filter into the tank to maintain pressure and high temperature. The steam pressure was monitored and bulk sterilization performed. The suspension was then aseptically filled using a Weiler 624 BFS machine into 3 mL polypropylene vials, with a target volume of 2.5 mL and a final concentration of 0.075 mg/mL of the compound of Formula (I). Each vial contained 0.15 mg of Form 1 of the compound of Formula (I) in 2 mL phosphate buffered saline. The vials were labeled and packaged.

For a 0.115 mg/mL Formulation:

Water, sodium carboxymethylcellulose (CMC) (5.55 g/kg), polysorbate 80 (0.50 g/kg), sodium phosphate monobasic monohydrate (0.268 g/kg), sodium phosphate dibasic heptahydrate (2.44 g/kg), and sodium chloride (9.11 g/kg) were added to a 300 L first tank. The aqueous solution in the first tank was then filtered through a 0.2 μm polyethersulfone (PES) filter into a second tank, where it was bulk sterilized. 0.15 g/kg of polymorph Form 1 of the compound of Formula (I), water for injection, and 0.5 g/kg polysorbate 80 were added to a 30 L third tank to form a slurry containing 115 μg/mL of the compound of Formula (I). The slurry was sterilized by overhead steam pressure, then added to the second tank containing the aqueous solution. The slurry was homogenized at 30 Hz and manufactured using principles of overkill cycle (F₀ ≥30). The mixture was aseptically mixed with sterile diluent to form a suspension with a concentration of 0.115 mg/mL of the compound of Formula (I). The bulk solution temperature was maintained at 250° F. as monitored by bottom TC and overhead pressure was maintained greater than the steam pressure introduced in the tank jacket (˜>5 psi). To maintain overhead pressure during bleeding of the top valve next to the mixer to monitor TC above the tank, steam was introduced via the air filter into the tank to maintain pressure and high temperature. The steam pressure was monitored and bulk sterilization performed. The suspension was then aseptically filled using a Weiler 624 BFS machine into 3 mL polypropylene vials, with a target volume of 2.5 mL and a final concentration of 0.035 mg/mL of the compound of Formula (I). Each vial contained 0.23 mg of Form 1 of the compound of Formula (I) in 2 mL phosphate buffered saline. The vials were labeled and packaged.

Example 2: Polymorph Screen

A polymorph form of the compound of Formula (I) was used in the ready-to-use formulations described in Example 1, above. A polymorph screen was performed on the compound of Formula (I) to determine solubility, polymorphism, and thermodynamic stability.

A. Analysis of the Starting Solid

X-ray powder diffraction (XRD), differential scanning calorimetry (DSC), and thermal gravimetric analysis (TGA) scans of the starting solid compound of Formula (I) indicated that the starting solid was a crystalline material and was a mixture of Form 1 and a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water. According to the DSC scan (FIG. 12B), the solid showed a wide endotherm between 50° C.-100° C.; it also showed a sharp exotherm at 284° C.; and the solid eventually melted at 364° C. According to the TGA scan (FIG. 12C), a 1.4% weight loss was observed before 100° C.

The solubility of the starting solid was measured by the gravimetric method and indicated that the compound had low solubility at RT and at 50° C. in all solvents tested except DMF and DMSO. Results from the solubility data test at RT and at 50° C. are shown in Table 3.

TABLE 3 Solubility data of the starting solid (a non-stoichiometric or stoichiometric hydrate of Form 1) Solubility at RT Solubility at 50° C. Solvents (mg/mL) (mg/mL) Acetone 1 1 Acetonitrile ~0 0 MeOH 1 1 Toluene 1 1 EtOH 2 2 IPAc ~0 ~0 EA 1 1 MtBE ~0 ~0 IPA 2 5 MEK 1 1 MA ~0 ~0 n-Propanol 1 2 MIBK 1 1 n-Butyl acetate ~0 ~0 water 1 1 Heptane ~0 ~0 n-Butanol 1 2 DMSO n/a n/a DMF 12 16 DCM 2 2 Acetic acid ~0 3

Reslurry experiments in various solvents were performed. Approximately 30-80 mg of the starting solid (a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water) was slurried in 39 different solvents (pure and binary solvents; the ratio of organic solvent/water (V/V) was 95%/5%) at RT and 50° C. for 5 days. Three solvates, one hydrate, and eleven non-solvated forms were identified. A “*” after a particular Form, e.g., Form 2*, indicates that the forms had similar XRD scans with minor differences and were considered to belong to the same class. Generally, the identified forms showed multiple endotherms/exotherms on differential scanning calorimetry (DSC) scans; Form 9 showed a single endotherm. XRD of both wet and dry samples were scanned (FIG. 12A (dry sample)). The data is shown in Tables 4 and 5 below.

TABLE 4 Results of slurry experiments at RT Crystalline Form Crystalline Form Solvent (wet/dry) Solvent (wet/dry) Acetone Solvate 1 Form 2 Acetone/water Solvate 2 Form 4** Acetonitrile Form 2 Form 1 Acetonitrile/water Form 12 Form 1 MeOH Form 13 Form 1 MeOH/water Form 12 Form 1 Toluene Form 1 Form 2* Toluene/water Form 13 Form 1 EtOH Form 2* Form 3 EtOH/water Solvate 3 Form 2 IPAc Form 3 Form 4 IPAc/water Form 12 Form 1 EA Form 4* Form 5 EA/water Form 12 Form 1 MtBE Form 5* Form 6 MtBE/water Form 12 Form 1 IPA Form 6 Form 7 IPA/water Form 6 Form 6 MEK Form 7 Form 4 MEK/water Form 7 Form 7 MA Form 4 Form 4* MA/water Form 13 Form 1 n-Propanol Form 4* Form 8 n-Propanol/water Form 2** Form 2** MIBK Form 8 Form 3 MIBK/water Form 12 Form 1 n-Butyl Form 3* Form 1 n-Butyl Form 13 Form 12 acetate acetate/water Water Form 13 Form 1 Heptane/water Form 13 Form 12 Heptane Form 1 Form 9 n-Butanol/water Form 13 Form 13 n-Butanol Form 9 Form 10 DMSO/water amorphous Form 10 DMSO amorphous Form 11 DMF/water Form 11 Form 11 DMF Form 11 Form 1 DCM/water Form 13 Form 1 DCM Form 1 Form 2

TABLE 5 Results of slurry experiments at 50° C. Crystalline Form Crystalline Form Solvent (wet/dry) Solvent (wet/dry) Acetone Solvate 2 Form 4** Acetone/water Form 4** Form 4** Acetonitrile Form 2* Form 2 Acetonitrile/water Form 13 Form 13 MeOH Form 1 Form 1 MeOH/water Form 13 Form 13 Toluene Form 1 Form 1 Toluene/water Form 13 Form 13 EtOH Form 2* Form 2* EtOH/water Form 9 Form 9 IPAc Form 9 Form 9 IPAc/water Form 13 Form 13 EA Form 4* Form 4 EA/water Form 4* Form 4* MtBE Form 5* Form 4 MtBE/water Form 13 Form 13 IPA Form 6 Form 6 IPA/water Form 6 Form 6 MEK Form 7 Form 7 MEK/water Form 7 Form 7 MA Form 4 Form 4 MA/water Form 12 Form 4 n-Propanol Form 4 Form 4** n-Propanol/water Form 9 Form 9 MIBK Form 8 Form 8 MIBK/water Form 13 Form 1 n-Butyl Form 9 Form 9 n-Butyl Form 13 Form 1 acetate acetate/water water Form 13 Form 13 Heptane/water Form 13 Form 1 Heptane Form 13 Form 13 n-Butanol/water Form 13 Form 1 n-Butanol Form 9 Form 9 DMSO/water Amorphous Form 10 DMSO Amorphous Form 10* DMF/water Form 11 Form 11 DMF Form 11 Form 11* DCM/water Form 13 Form 1 DCM Form 13 Form 13

The slurry experiments identified 3 solvated forms from wet samples (Solvates 1, 2, and 3); 2 non-stoichiometric hydrates of Form 1 (Forms 12 and 13); and 11 non-solvated forms (Forms 1-11). In some instances, similar XRD scans with minor differences were obtained. These were considered to be part of the same class (e.g., the same form). For example, XRD scans of Form 2 and Form 2* were similar and were considered to belong to the same class. The solvated forms were obtained from wet sample analysis; after drying, the sample indicated a different XRD.

Solvate 1 was obtained from acetone at RT, and after drying, a low crystallinity solid was generated. Solvate 2 was obtained from acetone (at RT) and acetone/water (at RT), and after drying, Form 4** was generated. Solvate 3 was obtained from EtOH/water at RT, and after drying, Form 2 was generated.

B. Form 1

The experiments that generated Form 1 are shown in Table 6, below. Form 1 was generally obtained from drying of Form 13 or Form 12. Form 1 may be considered as a dehydrated hydrate. Reslurry in many binary solvents (with 5% water) generated Form 1. Purity of the residual solid was 98.9%. KF of Form 1 (one sample) solid was 5.8%; residual MeOH of Form 1 solid was 0.01%. A TGA scan of fully dried Form 1 solid was performed (FIG. 1C). A 0.33% weight loss was observed before 100° C.

Form 1 showed sharp crystalline peaks on the XRD scan (FIG. 1A). The XRD peaks of Form 1 are shown in Table 7, below. According to the DSC scan (FIG. 1B), the solid showed a wide endotherm between 50-100° C.; it showed a sharp exotherm at 281° C.; and the melting point was 363° C. Form 1 has a primitive orthorhombic crystal structure with the approximate dimensions: a [Å]=29.062, b [Å]=23.945, c [Å]=7.245 and an approximate volume cell of [Å³/cell]=5,041.7 and a space group defined as Pbca (61).

The Form 1 solid was dried at 75° C. under vacuum overnight, and XRD, DSC, and TGA scans were performed. Comparison of the first and the second XRD scans (after drying at 75° C. under vacuum overnight), showed no change. However, the DSC scans indicated the absence of endotherm. The loss of the early peak on the DSC scan had no effect on the XRD trace, showing that the wide endotherm between 50-100° C. on DSC scan was due to the free solvent.

The Form 1 solid was heated in a DSC chamber to 305° C. (past the endotherm/exotherm around 280° C.), and then scanned by XRD. Comparison of the first and the third XRD and DSC scans shows that after heating to 305° C., Form 1 converted to Form 9. It can be concluded that the endotherm/exotherm around 280° C. might be due to melting/crystallization events.

Form 1 tended to convert to a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water (Form 13) at RH above 4050%. The hydrate lost its water below 30% RH. Form 1 converts to Form 13 when exposed to air.

The dynamic vapor sorption (DVS) scan of Form 1 solid showed a 17% water absorption at 90% RH (FIG. 1D). The XRD data indicated that the solid used in the DVS test converted to the hydrate form before the start of the DVS test. However, at 0% RH, water was lost, perhaps indicating that the solid was Form 1.

TABLE 6 Summary of experiments that generated Form 1 Form Solvent Temperature Wet Dry Form 1 MeOH RT Form 13 Form 1 MeOH 50° C. Form 1 Form 1 Toluene RT Form 1 Form 1 Toluene 50° C. Form 1 Form 1 water RT Form 13 Form 1 Heptane RT Form 1 Form 1 DCM RT Form 1 Form 1 Acetonitrile/water RT Form 12 Form 1 MeOH/water RT Form 12 Form 1 Toluene/water RT Form 13 Form 1 IPAc/water RT Form 13 Form 1 EA/water RT Form 12 Form 1 MtBE/water RT Form 12 Form 1 MA/water RT Form 13 Form 1 MIBK/water RT Form 12 Form 1 MIBK/water 50° C. Form 13 Form 1 DCM/water RT Form 13 Form 1 DCM/water 50° C. Form 13 Form 1 n-Butyl acetate/water 50° C. Form 13 Form 1 Heptane/water 50° C. Form 13 Form 1 n-Butanol/water 50° C. Form 13 Form 1 *Amount of water in binary solvents is 5%

TABLE 7 XRD peaks of Form 1 2-Theta d (A) BG Height I % Area I % FWHM 5.778 15.2835 57 97 28.3 1765 18.5 0.309 6.801 12.9871 19 343 100 8306 87.1 0.412 9.26 9.5427 20 178 51.9 3884 40.7 0.371 12.421 7.1203 30 231 67.3 4862 51 0.358 13.919 6.357 35 147 42.9 3668 38.5 0.424 14.501 6.1033 40 133 38.8 3439 36.1 0.44 16.5 5.3681 47 196 57.1 4286 44.9 0.372 17.26 5.1333 53 46 13.4 560 5.9 0.207 18.52 4.7868 68 342 99.7 9539 100 0.474 19.161 4.6282 54 215 62.7 4130 43.3 0.327 20.302 4.3706 49 133 38.8 2823 29.6 0.361 20.619 4.304 43 80 23.3 2047 21.5 0.435 23.056 3.8543 41 38 11.1 765 8 0.342 24.642 3.6098 33 175 51 7235 75.8 0.703 25.302 3.5171 86 80 23.3 2345 24.6 0.498 26.1 3.4113 83 69 20.1 1545 16.2 0.381 27.46 3.2453 52 46 13.4 872 9.1 0.322 28.739 3.1038 39 84 24.5 2146 22.5 0.434 30.444 2.9337 34 32 9.3 1080 11.3 0.54 33.302 2.6882 30 27 7.9 683 7.2 0.405

C. Forms 2, 2*, and 2***

The experiments that generated Forms 2, 2*, and 2** are shown in Table 8, below. XRD scans of Forms 2, 2* and 2** were performed (FIGS. 2A, 2D, and 2G show the XRD scans of Forms 2, 2*, and 2**, respectively). The XRD peaks of Forms 2 and 2* are shown in Tables 9 and 10, below, respectively. DSC scans were also performed (FIGS. 2B, 2E, and 2H show the DSC scans of Forms 2, 2*, and 2**, respectively). According to the DSC scans, Forms 2, 2* and 2** each showed a wide endotherm between 50° C.-100° C., and multiple endotherms and exotherms before melting at 363° C. The wide endotherm before 100° C. may be due to the containment of water/solvent in the solid. Form 2 was obtained from acetonitrile; Form 2* from ethanol; Form 2** from n-propanol/5% water.

A TGA scan of Form 2 (FIG. 2C) showed a 2.7% weight loss before 116° C. FIG. 2F shows the TGA scan of Form 2*

A PLM photo of Form 2 was taken, indicating that the particle size of this solid was around 50 um.

The Form 2 solid was heated in a DSC machine to 90° C. (past the wide endotherm between 50-100° C.); to 270° C. (past the endotherm/exotherm around 240° C.); and finally to 330° C. (past the exotherm around 330° C.). The residual solid was analyzed by XRD. According to the first and second XRD and DSC scans, the form did not change before and after heating to 90° C. The wide endotherm between 50-100° C. might be free solvent or hydrate. According to the first and third XRD and DSC scans, after heating a Form 2 sample to 270° C., the solid converted to low crystalline solids. According to the first and fourth XRD and DSC scans, after heating the sample to 330° C., the solid converted to Form 9. Thus, the exotherm around 290° C. was a re-crystallization event. According to an XRD and DSC overlay, the behavior of Form 2* was similar to Form 2.

Residual acetonitrile and EtOH in Form 2 and 2* was not detected.

TABLE 8 Summary of experiments that generated Forms 2, 2*, and 2** Form Solvent Temperature Wet Dry Form 2 Acetonitrile RT Form 2 Form 2 Acetonitrile 50° C. Form 2* Form 2 EtOH/water RT Solvate 3 Form 2 Form 2* EtOH RT Form 2* Form 2* EtOH 50° C. Form 2* Form 2* Acetonitrile 50° C. Form 2* Form 2 Form 2** n-Propanol/water RT Form 2** Form 2** *Amount of water in binary solvents is 5%

TABLE 9 XRD peaks of Form 2 2-Theta d (A) BG Height I % Area I % FWHM 7.021 12.5802 164 2202 54.1 36151 38.2 0.279 8.298 10.6462 156 194 4.8 2332 2.5 0.204 10.399 8.5 193 397 9.8 6246 6.6 0.267 11.258 7.8531 206 151 3.7 1407 1.5 0.158 12.239 7.2259 181 287 7 5980 6.3 0.354 14.1 6.2759 186 648 15.9 14147 15 0.371 14.597 6.0632 195 182 4.5 7983 8.4 0.746 16.18 5.4734 235 201 4.9 4033 4.3 0.341 16.561 5.3484 251 280 6.9 8382 8.9 0.509 17.033 5.2013 288 160 3.9 1810 1.9 0.192 17.639 5.0238 295 366 9 3542 3.7 0.165 18.878 4.6968 316 1210 29.7 29303 31 0.412 19.22 4.614 333 585 14.4 21169 22.4 0.615 19.863 4.4662 340 95 2.3 437 0.5 0.078 20.411 4.3474 385 86 2.1 671 0.7 0.133 21.48 4.1335 532 1944 47.8 61345 64.8 0.536 22.04 4.0297 647 4071 100 94605 100 0.395 23.036 3.8576 634 142 3.5 1478 1.6 0.177 24.24 3.6686 497 1688 41.5 28976 30.6 0.292 25.561 3.482 422 120 2.9 2545 2.7 0.361 25.918 3.4349 365 271 6.7 11426 12.1 0.717 26.379 3.3759 349 497 12.2 15133 16 0.518 26.739 3.3313 387 181 4.4 2845 3 0.267 27.979 3.1863 297 235 5.8 4050 4.3 0.293 29.043 3.072 338 347 8.5 4584 4.8 0.225 29.661 3.0094 321 310 7.6 7879 8.3 0.432 30.204 2.9565 355 135 3.3 1501 1.6 0.189 31.58 2.8308 232 206 5.1 3991 4.2 0.329 32.602 2.7443 193 63 1.5 1129 1.2 0.305

TABLE 10 XRD peaks of Form 2* 2-Theta d (A) BG Height I % Area I % FWHM 4.859 18.1701 127 87 1.2 1714 1.9 0.335 7.119 12.4067 148 3587 48.4 44853 50.4 0.213 8.321 10.6166 149 407 5.5 4871 5.5 0.203 10.439 8.4669 186 1184 16 13629 15.3 0.196 11.319 7.8109 190 413 5.6 4673 5.3 0.192 12.3 7.1899 179 1010 13.6 13220 14.9 0.223 12.803 6.9089 182 140 1.9 1587 1.8 0.193 14.121 6.2667 179 1966 26.5 27290 30.7 0.236 14.559 6.0791 199 169 2.3 4381 4.9 0.441 16.236 5.4546 244 436 5.9 5696 6.4 0.222 16.62 5.3297 271 674 9.1 7919 8.9 0.2 17.059 5.1935 313 629 8.5 6279 7.1 0.17 17.699 5.0071 303 1094 14.7 12619 14.2 0.196 18.858 4.7018 359 2334 31.5 31734 35.7 0.231 19.321 4.5903 325 1650 22.2 28313 31.8 0.292 19.823 4.4751 412 127 1.7 582 0.7 0.078 20.321 4.3665 327 333 4.5 3361 3.8 0.172 21.479 4.1336 451 3245 43.8 56365 63.3 0.295 22.119 4.0154 612 7417 100 89000 100 0.204 22.782 3.9 536 327 4.4 11890 13.4 0.618 23.098 3.8475 466 638 8.6 11127 12.5 0.296 24.3 3.6597 361 4873 65.7 61170 68.7 0.213 25.599 3.4769 487 475 6.4 7278 8.2 0.26 25.88 3.4399 541 562 7.6 10968 12.3 0.332 26.361 3.3782 372 1289 17.4 20859 23.4 0.275 26.739 3.3312 266 660 8.9 13196 14.8 0.34 27.938 3.1909 284 560 7.6 9888 11.1 0.3 28.641 3.1142 319 210 2.8 2324 2.6 0.188 29.398 3.0357 357 100 1.3 2376 2.7 0.404 29.779 2.9977 295 708 9.5 13168 14.8 0.316 30.3 2.9473 283 451 6.1 6600 7.4 0.249 31.658 2.8239 239 667 9 9228 10.4 0.235 32.519 2.7511 221 191 2.6 2896 3.3 0.258 33.903 2.6419 213 72 1 876 1 0.207 34.82 2.5744 229 110 1.5 3822 4.3 0.591 35.504 2.5264 230 97 1.3 3876 4.4 0.679

D. Form 3

The experiments that generated Form 3 are shown in Table 11, below. XRD and DSC scans of Form 3 were taken (FIGS. 3A and 3B, respectively). Table 12, below, shows the XRD peaks of Form 3. Multiple exotherms and endotherms were observed from the DSC scan of Form 3.

A TGA scan of Form 3 was taken (FIG. 3C) and showed a 1.6% weight loss of the solid before 81° C., followed by a 1.7% weight loss between 81° C. and 169° C.

Form 3 was obtained from IPAc at RT, while Form 3* was obtained from reslurry in n-butyl acetate.

TABLE 11 Summary of experiments that generated Form 3 and Form 3* Form Solvent Temperature Wet Dry Form 3 IPAc RT Form 3 Form 3 n-Butyl acetate RT Form 3* Form 3 Form 3* n-Butyl acetate RT Form 3* Form 3

TABLE 12 XRD peaks of Form 3 2-Theta d (A) BG Height I % Area I % FWHM 5.024 17.5739 231 87 4.4 845 1.9 0.165 6.34 13.9294 368 1030 52.5 12361 27.5 0.204 7.219 12.2357 182 1962 100 36491 81.1 0.316 8.441 10.4665 188 159 8.1 3261 7.2 0.349 9.237 9.5659 207 320 16.3 3365 7.5 0.179 10.561 8.37 240 278 14.2 6270 13.9 0.383 10.998 8.0381 217 849 43.3 17119 38.1 0.343 11.46 7.715 256 87 4.4 662 1.5 0.129 12.439 7.11 215 311 15.9 6502 14.5 0.355 12.865 6.8756 209 92 4.7 1599 3.6 0.295 14.22 6.2233 231 522 26.6 12265 27.3 0.399 15.524 5.7034 273 311 15.9 2957 6.6 0.162 16.021 5.5276 309 218 11.1 2669 5.9 0.208 16.78 5.2792 368 330 16.8 3780 8.4 0.195 17.181 5.1567 384 99 5 2614 5.8 0.449 17.782 4.9837 428 496 25.3 6264 13.9 0.215 18.381 4.8227 509 551 28.1 5102 11.3 0.157 19.02 4.6622 447 589 30 20513 45.6 0.592 19.758 4.4896 487 423 21.6 14362 31.9 0.577 20.8 4.267 520 214 10.9 1518 3.4 0.121 21.19 4.1893 408 418 21.3 4581 10.2 0.186 21.6 4.1107 553 1017 51.8 41986 93.3 0.702 22.181 4.0044 662 1736 88.5 44981 100 0.44 23.185 3.8333 508 259 13.2 3327 7.4 0.218 24.44 3.6392 467 1441 73.4 29510 65.6 0.348 25.198 3.5313 551 232 11.8 1362 3 0.1 25.618 3.4745 557 79 4 365 0.8 0.079 26.103 3.4109 512 180 9.2 7374 16.4 0.696 26.479 3.3634 475 306 15.6 11652 25.9 0.647 27.3 3.264 455 133 6.8 1016 2.3 0.13 28.04 3.1796 378 93 4.7 1485 3.3 0.271 28.82 3.0953 372 201 10.2 3455 7.7 0.292 29.258 3.0499 362 76 3.9 2580 5.7 0.577 29.88 2.9878 334 191 9.7 4011 8.9 0.357 31.802 2.8115 251 205 10.4 4094 9.1 0.34 32.62 2.7429 231 87 4.4 1109 2.5 0.217 32.943 2.7167 215 52 2.7 1107 2.5 0.362 33.961 2.6375 217 101 5.1 1686 3.7 0.284

E. Form 4

The experiments that generated Forms 4, 4*, and 4** are shown in Table 13, below. XRD of Forms 4, 4*, and 4** were taken (FIGS. 4A, 4D, and 4G, respectively). Tables 14 and 15, below, show the XRD peaks of Form 4 and Form 4*, respectively. DSC scans of Forms 4, 4*, and 4** were also performed (FIGS. 4B, 4E, and 4H, respectively). According to the DSC scans, Form 4 showed a wide endotherm between 50° C.-100° C., followed by multiple endotherms/exotherms, and then melted at around 367° C. Forms 4* and 4** showed similar DSC patterns as Form 4.

TGA scans of Form 4, Form 4*, and Form 4** were taken (FIGS. 4C, 4F, and 4I, respectively). For Form 4, there was an 8.3% weight loss before 200° C.; for Form 4*, there was a 4.4% weight loss before 102° C., followed by a 0.5% weight loss between 102° C. and 250° C.; and for Form 4**, there were three stages of weight loss, which were 2.8%, 1.9%, and 1.3%, respectively.

These solid forms were obtained from methyl acetate, n-propanol, MIBK, MtBE, ethyl acetate, acetone/water, and ethyl acetate/water.

TABLE 13 Summary of experiments that generated Forms 4, 4*, and 4** Form Solvent Temperature Wet Dry Form 4 EA RT Form 4* Form 4 EA 50° C. Form 4* Form 4 MA RT Form 4 Form 4 MA 50° C. Form 4 Form 4 MA/water 50° C. Form 12 Form 4 MtBE 50° C. Form 5* Form 4 n-Propanol RT Form 4 Form 4* Form 4* EA RT Form 4* Form 4* EA 50° C. Form 4* Form 4 EA/water 50° C. Form 4* Form 4* n-Propanol RT Form 4 Form 4* Form 4** Acetone/water RT Solvate 2 Form 4** Acetone 50° C. Solvate 2 Form 4** n-Propanol 50° C. Form 4 Form 4** Acetone/water 50° C. Form 4** Form 4** *Amount of water in binary solvents is 5%

TABLE 14 XRD peaks of Form 4 2-Theta d (A) BG Height I % Area I % FWHM 3.433 25.7129 197 48 1 697 0.7 0.247 7.019 12.5829 222 3897 77.3 66968 69.4 0.292 8.659 10.203 242 448 8.9 8198 8.5 0.311 8.98 9.8395 223 219 4.3 7649 7.9 0.594 9.64 9.1672 251 516 10.2 6969 7.2 0.23 10.917 8.0978 210 77 1.5 1041 1.1 0.23 12.339 7.1673 220 465 9.2 9572 9.9 0.35 13.82 6.4023 268 501 9.9 11493 11.9 0.39 14.278 6.1981 271 192 3.8 7288 7.6 0.645 14.923 5.9314 288 172 3.4 1636 1.7 0.162 16.462 5.3804 310 329 6.5 3066 3.2 0.158 17.041 5.199 375 105 2.1 942 1 0.153 17.638 5.0241 435 1073 21.3 13511 14 0.214 18.281 4.8488 487 772 15.3 9782 10.1 0.215 19.52 4.5437 504 1590 31.5 31949 33.1 0.342 21.759 4.081 677 5040 100 96504 100 0.326 23.22 3.8275 693 1457 28.9 28109 29.1 0.328 25.12 3.5421 710 3091 61.3 69330 71.8 0.381 25.76 3.4556 455 827 16.4 22029 22.8 0.453 27.221 3.2733 419 180 3.6 2915 3 0.275 28.638 3.1145 409 210 4.2 4338 4.5 0.351 29.259 3.0498 461 568 11.3 11998 12.4 0.359 30.137 2.9629 409 149 3 1946 2 0.222 31.817 2.8102 253 110 2.2 4034 4.2 0.623 32.319 2.7677 245 137 2.7 3829 4 0.475

TABLE 15 XRD peaks of Form 4* 2-Theta d (A) BG Height I % Area I % FWHM 4.981 17.7282 270 684 15.8 12231 12.6 0.304 7.22 12.2329 244 3416 79 65744 67.8 0.327 8.459 10.4447 202 335 7.7 4814 5 0.244 10.56 8.3707 219 629 14.5 10739 11.1 0.29 11.42 7.7419 240 203 4.7 2908 3 0.244 12.42 7.1209 221 614 14.2 11445 11.8 0.317 13.019 6.7947 238 59 1.4 423 0.4 0.122 14.26 6.2057 227 1052 24.3 20787 21.4 0.336 16.318 5.4274 409 85 2 665 0.7 0.133 16.722 5.2973 332 496 11.5 8980 9.3 0.308 17.199 5.1515 393 226 5.2 3448 3.6 0.259 17.82 4.9733 402 725 16.8 8502 8.8 0.199 18.98 4.672 432 1352 31.3 36895 38.1 0.464 19.44 4.5623 439 990 22.9 28546 29.4 0.49 20.46 4.3371 444 119 2.8 1163 1.2 0.166 21.58 4.1144 458 1982 45.8 71568 73.8 0.614 22.22 3.9974 837 4325 100 96937 100 0.381 23.16 3.8373 758 114 2.6 1085 1.1 0.162 24.42 3.6421 522 2466 57 48977 50.5 0.338 25.679 3.4663 590 252 5.8 5211 5.4 0.352 26.5 3.3607 470 671 15.5 23177 23.9 0.587 26.95 3.3056 356 313 7.2 3645 3.8 0.198 28.118 3.1709 385 255 5.9 5045 5.2 0.336 29.9 2.9858 360 383 8.9 13112 13.5 0.582 30.421 2.9359 346 239 5.5 5602 5.8 0.398 31.779 2.8134 293 336 7.8 5905 6.1 0.299 32.618 2.743 267 124 2.9 1934 2 0.265

F. Forms 5 and 5*

The experiments that generated Forms 5 and 5* are shown in Table 16, below. XRD scans of Forms 5 and 5* were taken (FIGS. 5A and 5D, respectively). The XRD peaks of Form 5 are shown in Table 17, below. A DSC scan of Form 5 was also performed and showed a wide endotherm between 50° C.-100° C., and multiple endotherms and exotherms before melting at 363° C. (FIG. 5B).

A TGA scan of Form 5 solid showed a 3.1% weight loss before 100° C., followed by a 1.7% weight loss between 100° C. and 250° C. (FIG. 5C).

Forms 5 and 5* were obtained from slurrying Form 12 in MtBE at RT and 50° C. Wet solid showed Form 5*, while dry solid indicated Form 5.

TABLE 16 Summary of experiments that generated Forms 5 and 5* Form Solvent Temperature Wet Dry Form 5 MtBE RT Form 5* Form 5 Form 5* MtBE RT Form 5* Form 5 MtBE 50° C. Form 5* Form 4

TABLE 17 XRD peaks of Form 5 2-Theta d (A) BG Height I % Area I % FWHM 5.098 17.3185 260 155 2.4 2464 2.1 0.27 6.38 13.8428 256 1778 27.7 34733 29.6 0.332 7.28 12.1332 214 3964 61.6 78158 66.5 0.335 8.518 10.3715 234 241 3.7 3170 2.7 0.224 9.24 9.5627 227 472 7.3 6614 5.6 0.238 10.639 8.3083 266 765 11.9 20508 17.5 0.456 11.019 8.0226 242 1596 24.8 37620 32 0.401 11.483 7.6998 398 133 2.1 949 0.8 0.121 12.44 7.1091 246 584 9.1 11910 10.1 0.347 12.94 6.8358 249 152 2.4 4189 3.6 0.469 14.301 6.1883 279 1114 17.3 22226 18.9 0.339 14.839 5.9648 300 167 2.6 5989 5.1 0.61 15.581 5.6827 404 376 5.8 4045 3.4 0.183 16.08 5.5073 452 459 7.1 9013 7.7 0.334 16.357 5.4146 509 260 4 11967 10.2 0.782 16.839 5.2606 521 473 7.4 7195 6.1 0.259 17.254 5.1351 550 258 4 4373 3.7 0.288 17.839 4.968 562 414 6.4 4207 3.6 0.173 18.439 4.8078 667 590 9.2 5946 5.1 0.171 19.059 4.6527 616 1603 24.9 35964 30.6 0.381 19.5 4.5486 671 1163 18.1 30384 25.9 0.444 20.882 4.2506 850 305 4.7 2860 2.4 0.159 21.679 4.0959 935 2272 35.3 66194 56.4 0.495 22.28 3.9867 1083 6430 100 117449 100 0.311 23.221 3.8273 856 564 8.8 9429 8 0.284 24.461 3.6361 697 4250 66.1 74709 63.6 0.299 25.276 3.5206 726 170 2.6 1349 1.1 0.135 26.081 3.4137 756 442 6.9 17518 14.9 0.674 26.52 3.3582 689 1014 15.8 34615 29.5 0.58 28.139 3.1686 528 306 4.8 4846 4.1 0.269 28.821 3.0952 533 463 7.2 7067 6 0.259 29.94 2.9819 499 755 11.7 15565 13.3 0.35 30.458 2.9324 435 467 7.3 9861 8.4 0.359 31.86 2.8065 343 648 10.1 13697 11.7 0.359 32.642 2.741 314 125 1.9 2403 2 0.327 34.002 2.6344 298 123 1.9 1956 1.7 0.27

G. Form 6

The experiments that generated Form 6 are shown in Table 18, below. XRD and DSC scans of Form 6 were taken (FIGS. 6A and 6B, respectively). According to the DSC scan, the solid showed a small exotherm at 250° C. and a sharp melting endotherm at 358° C.

Form 6 was obtained by slurrying starting material in IPA and IPA/5% water at RT and 50° C.

TABLE 18 Summary of experiments that generated Form 6 Form Solvent Temperature Wet Dry Form 6 IPA RT Form 6 Form 6 IPA 50° C. Form 6 Form 6 IPA/water RT Form 6 Form 6 IPA/water 50° C. Form 6 Form 6 *Amount of water in binary solvents is 5%

H. Form 7

The experiments that generated Form 7 are shown in Table 19, below. XRD and DSC scans of Form 7 were taken (FIGS. 7A and 7B, respectively). The XRD peaks of Form 7 are shown in Table 20, below. According to the DSC scan, the solid showed two exotherms at 227° C. and 299° C., followed by a melting endotherm at 365° C. Form 7 showed low degree of crystallinity on XRD. The double exotherm on the DSC scans may be associated with the low crystallinity observed on the XRD scan.

A TGA scan of Form 7 solid showed a 12% weight loss before 200° C. (FIG. 7C).

Form 7 was obtained from MEK and MEK/5% water at RT and 50° C.

TABLE 19 Summary of experiments that generated Form 7 Form Solvent Temperature Wet Dry Form 7 MEK RT Form 7 Form 7 MEK 50° C. Form 7 Form 7 MEK/water RT Form 7 Form 7 MEK/water 50° C. Form 7 Form 7 *Amount of water in binary solvents is 5%

TABLE 20 XRD peaks of Form 7 2-Theta d (A) BG Height I % Area I % FWHM 4.94 17.8745 362 1384 23.3 50829 29.2 0.624 7.06 12.5111 286 3171 53.3 69159 39.8 0.371 8.759 10.0876 370 628 10.6 9606 5.5 0.26 9.9 8.9272 429 537 9 11110 6.4 0.352 10.881 8.1241 546 879 14.8 16425 9.4 0.318 11.84 7.4681 588 413 6.9 7187 4.1 0.296 12.997 6.8061 463 135 2.3 1351 0.8 0.17 14.404 6.1442 604 126 2.1 3331 1.9 0.449 15.1 5.8626 791 596 10 8819 5.1 0.252 15.92 5.5622 792 593 10 24460 14.1 0.701 16.581 5.3421 739 641 10.8 14919 8.6 0.396 18.5 4.7919 1066 1555 26.1 43174 24.8 0.472 19.4 4.5717 1087 930 15.6 17521 10.1 0.32 20.382 4.3535 1178 154 2.6 867 0.5 0.096 21.56 4.1183 1424 5949 100 173972 100 0.497 22.098 4.0192 1830 692 11.6 17678 10.2 0.434 23.22 3.8275 1749 1971 33.1 42151 24.2 0.364 24.203 3.6743 1776 351 5.9 11935 6.9 0.578 24.884 3.5751 1658 271 4.6 2378 1.4 0.149 25.759 3.4556 1416 492 8.3 19894 11.4 0.687 26.3 3.3858 1335 499 8.4 23631 13.6 0.805 27.34 3.2594 1192 307 5.2 4494 2.6 0.249 28.641 3.1142 1004 382 6.4 18030 10.4 0.802 29.078 3.0684 979 324 5.4 14234 8.2 0.747 30.28 2.9492 759 711 12 16004 9.2 0.383 31.985 2.7959 551 111 1.9 4816 2.8 0.738 33.402 2.6804 509 102 1.7 2060 1.2 0.343 34.24 2.6167 474 92 1.5 1901 1.1 0.351

I. Form 8

The experiments that generated Form 8 are shown in Table 21, below. XRD and DSC scans of Form 8 were taken (FIGS. 8A and 8B, respectively). The XRD peaks of Form 8 are shown in Table 22, below. According to the DSC scan, the solid showed two endotherms at 205° C. and 231° C., followed by an exotherm at 279° C., followed by a melting endotherm at 362° C. Form 8 showed a low degree of crystallinity on the XRD scan. The double exotherm on the DSC scan may confirm the low crystallinity seen on XRD (low crystalline material convert to higher crystallinity solid).

A TGA scan of Form 8 showed a 4.2% weight loss before 190° C., followed by a 3.9% weight loss between 190° C. and 261° C. (FIG. 8C).

Form 8 was obtained from MIBK at RT and 50° C. MIBK/5% water reslurry does not produce the same form.

TABLE 21 Summary of experiments that generated Form 8 Form Solvent Temperature Wet Dry Form 8 MIBK RT Form 8 Form 8 MIBK 50° C. Form 8 Form 8

TABLE 22 XRD peaks of Form 8 2-Theta d (A) BG Height I % Area I % FWHM 6.88 12.8368 318 2815 80.8 71578 51.7 0.432 10.699 8.2619 380 70 2 722 0.5 0.175 11.48 7.7016 344 466 13.4 9513 6.9 0.347 12.66 6.9866 348 136 3.9 1759 1.3 0.22 14.16 6.2496 435 166 4.8 3298 2.4 0.338 15.259 5.8017 483 269 7.7 6267 4.5 0.396 16.879 5.2484 669 333 9.6 7638 5.5 0.39 17.681 5.0121 780 1959 56.2 76035 54.9 0.66 19.618 4.5213 833 134 3.8 2110 1.5 0.268 21.5 4.1296 1116 3484 100 138450 100 0.676 24.244 3.6682 899 99 2.8 2643 1.9 0.454 27.559 3.234 753 366 10.5 11182 8.1 0.519 28.881 3.0889 636 279 8 8137 5.9 0.496 30.878 2.8935 403 87 2.5 1890 1.4 0.369 31.221 2.8624 386 69 2 1898 1.4 0.468

J. Form 9

The experiments that generated Form 9 are shown in Table 23, below. XRD and DSC scans of Form 9 were taken (FIGS. 9A and 9B, respectively). The XRD peaks of Form 9 are shown in Table 24, below. According to the DSC scan, the solid showed a single melting endotherm at 364° C. Form 9 has a primitive monoclinic crystal structure with the approximate dimensions: a [Å]=17.135, b [Å]=14.342, c [Å]=10.186; α(deg)=90, β(deg)=95.99, γ(deg)=90 and an approximate volume cell of [Å³/cell]=2,489.5 and a space group defined as P2_(1/c) (14).

A TGA scan of Form 9 showed a 0.28% weight loss before 100° C. (FIG. 9C).

Other forms, when heated to just before melting at 364° C., seemed to convert to Form 9. This has been confirmed for Forms 1 and 2.

A DVS scan of Form 9 showed a 0.8% water absorption at 90% RH. Form 9 did not change its form before and after the DVS scan (FIG. 9D).

TABLE 23 Summary of experiments that generated Form 9 Form Solvent Temperature Wet Dry n-Butanol RT Form 9 Form 9 Form 9 IPAc 50° C. Form 9 Form 9 n-Butyl acetate 50° C. Form 9 Form 9 n-Butanol 50° C. Form 9 Form 9 EtOH/water 50° C. Form 9 Form 9 n-Propanol/water 50° C. Form 9 Form 9 *Amount of water in binary solvents is 5%

TABLE 24 XRD peaks of Form 9 2-Theta d (A) BG Height I % Area I % FWHM 4.94 17.8746 21 895 100 23398 100 0.444 6.26 14.1076 21 34 3.8 513 2.2 0.257 10.099 8.7516 28 66 7.4 1172 5 0.302 11.883 7.4413 30 46 5.1 828 3.5 0.306 13.16 6.7221 27 37 4.1 400 1.7 0.184 15.341 5.771 39 71 7.9 1541 6.6 0.369 16.518 5.3622 40 93 10.4 1728 7.4 0.316 18.622 4.7608 46 260 29.1 7069 30.2 0.462 19.74 4.4938 80 138 15.4 1937 8.3 0.239 21.101 4.2068 64 342 38.2 8314 35.5 0.413 22.42 3.9622 56 77 8.6 1721 7.4 0.38 24.1 3.6897 58 198 22.1 3904 16.7 0.335 25.2 3.5311 63 157 17.5 3615 15.5 0.391 26.897 3.312 46 44 4.9 1307 5.6 0.505 28.577 3.121 35 54 6 1754 7.5 0.552 29.884 2.9874 32 30 3.4 477 2 0.254 30.926 2.8891 35 32 3.6 682 2.9 0.341

K. Forms 10 and 10*

The experiments that generated Forms 10 and 10* are shown in Table 25, below. XRD scans of Forms 10 and 10* were taken (FIGS. 10A and 10D, respectively). The XRD peaks of Form 10 are shown in Table 26, below. DSC scans of Forms 10 and 10* were also taken and indicated multiple endotherms/exotherms, followed by melting at 367° C. (FIGS. 10B and 10E, respectively).

Forms 10 and 10* were produced by drying of amorphous solids (obtained from DMSO and DMSO/water reslurry at RT and 50° C.). Both Form 10 and 10* are associated with DMSO.

A TGA scan of Form 10 solid showed a 0.6% weight loss before 100° C., followed by a 3.8% weight loss between 100° C. and 170° C., followed by a 7.1% weight loss between 170° C. and 260° C. (FIG. 10C).

TABLE 25 Summary of experiments that generated Forms 10 and 10* Form Solvent Temperature Wet Dry Form 10 DMSO RT amorphous Form 10 DMSO/water RT amorphous Form 10 DMSO/water 50° C. amorphous Form 10 Form 10* DMSO 50° C. amorphous Form 10* *Amount of water in binary solvents is 5%

TABLE 26 XRD peaks of Form 10 2-Theta d (A) BG Height I % Area I % FWHM 6.701 13.1792 148 1553 32.1 31364 34.4 0.343 8.3 10.6444 207 1026 21.2 17914 19.6 0.297 9.38 9.4203 212 1352 27.9 21528 23.6 0.271 10.819 8.1705 223 514 10.6 8714 9.6 0.288 11.919 7.4192 271 635 13.1 9435 10.3 0.253 12.919 6.8469 266 1160 24 22094 24.2 0.324 13.718 6.45 242 81 1.7 856 0.9 0.18 14.84 5.9646 271 244 5 4716 5.2 0.329 15.536 5.6988 312 147 3 1304 1.4 0.151 16.58 5.3424 392 1813 37.5 30451 33.4 0.286 17.821 4.9731 434 2208 45.6 58342 64 0.449 18.16 4.881 434 2862 59.2 89029 97.6 0.529 19.001 4.6667 1021 3215 66.5 45840 50.2 0.242 19.88 4.4623 1163 1454 30.1 19014 20.8 0.222 20.701 4.2873 1514 4838 100 78140 85.7 0.275 21.66 4.0994 596 4067 84.1 91229 100 0.381 23.38 3.8017 596 2251 46.5 64928 71.2 0.49 24.22 3.6717 663 4578 94.6 84228 92.3 0.313 26 3.4242 595 430 8.9 11172 12.2 0.442 27.12 3.2853 639 146 3 1986 2.2 0.231 27.88 3.1974 642 2073 42.8 48132 52.8 0.395 28.88 3.089 638 477 9.9 14155 15.5 0.504 29.867 2.9891 544 205 4.2 4572 5 0.379 30.32 2.9454 528 568 11.7 11936 13.1 0.357 31.098 2.8735 517 443 9.2 5841 6.4 0.224 31.661 2.8236 433 118 2.4 953 1 0.137 33.379 2.6822 433 311 6.4 9235 10.1 0.505 34.22 2.6181 444 281 5.8 6059 6.6 0.367 34.822 2.5743 460 84 1.7 2707 3 0.548 35.438 2.5309 465 89 1.8 858 0.9 0.164

L. Forms 11 and 11*

The experiments that generated Forms 11 and 11* are shown in Table 27, below. XRD scans of Forms 11 and 11* were taken (FIGS. 11A and 11D, respectively). The XRD peaks of Form 11 and Form 11* are shown in Tables 28 and 29, below, respectively. DSC scans of Forms 11 and 11* were also taken (FIGS. 11B and 11E, respectively). According to the DSC scans, the solid showed multiple endotherms/exotherms and eventually melted at 368° C. Amorphous halo was observed in the XRD of both Forms. The double exotherm on the DSC of both forms may be also associated with the amorphous halo observed on XRD scans.

TGA scans of Form 11 and 11* were taken (FIGS. 11C and 11F, respectively). Form 11 solids showed a 0.8% weight loss before 100° C., followed by a 7.0% weight loss between 100° C. and 249° C. Form 11* solids showed a 1.0% weight loss before 100° C., and followed by a 7.0% weight loss before 250° C.

Forms 11 and 11* were obtained from DMF and DMF/5% water at RT and 50° C.

TABLE 27 Summary of experiments that generated Forms 11 and 11* Form Solvent Temperature Wet Dry Form 11 DMF RT Form 11 Form 11 DMF 50° C. Form 11 Form 11* DMF/water RT Form 11 Form 11 DMF/water 50° C. Form 11 Form 11 Form 11* DMF 50° C. Form 11 Form 11* *Amount of water in binary solvents is 5%

TABLE 28 XRD peaks of Form 11 2-Theta d (A) BG Height I % Area I % FWHM 6.42 13.7554 19 496 81.7 9502 100 0.326 8.421 10.4908 20 335 55.2 5775 60.8 0.293 8.86 9.9726 24 166 27.3 4268 44.9 0.437 10.859 8.1404 21 91 15 1292 13.6 0.241 12.479 7.0871 44 83 13.7 1004 10.6 0.206 12.977 6.8165 29 51 8.4 1542 16.2 0.514 14.519 6.0957 28 91 15 1421 15 0.265 16.801 5.2727 57 104 17.1 2226 23.4 0.364 17.801 4.9787 103 358 59 5109 53.8 0.243 18.519 4.7871 101 607 100 8460 89 0.237 18.861 4.7011 102 125 20.6 1763 18.6 0.24 19.922 4.453 85 383 63.1 7376 77.6 0.327 20.258 4.38 79 180 29.7 5778 60.8 0.546 20.899 4.247 76 105 17.3 1291 13.6 0.209 21.738 4.085 86 55 9.1 757 8 0.234 22.441 3.9585 94 471 77.6 7125 75 0.257 22.859 3.8871 78 167 27.5 3724 39.2 0.379 24.458 3.6365 60 298 49.1 4544 47.8 0.259 26.82 3.3213 45 195 32.1 4777 50.3 0.416 29 3.0764 43 99 16.3 3112 32.8 0.534 29.524 3.023 63 37 6.1 190 2 0.087 31.04 2.8788 38 46 7.6 826 8.7 0.305 31.825 2.8095 36 56 9.2 737 7.8 0.224 32.456 2.7563 31 40 6.6 857 9 0.364

TABLE 29 XRD peaks of Form 11* 2-Theta d (A) BG Height I % Area I % FWHM 6.441 13.7116 24 424 93.4 8643 100 0.347 6.944 12.7196 20 84 18.5 2078 24 0.421 8.518 10.3718 22 227 50 4871 56.4 0.365 8.86 9.9721 23 147 32.4 3581 41.4 0.414 10.859 8.141 26 107 23.6 1695 19.6 0.269 12.519 7.0648 34 90 19.8 2165 25 0.409 13.021 6.7935 31 54 11.9 1517 17.6 0.478 14.618 6.0547 32 76 16.7 1605 18.6 0.359 16.638 5.3238 55 115 25.3 2410 27.9 0.356 17.838 4.9684 71 368 81.1 6709 77.6 0.31 18.522 4.7864 130 454 100 7473 86.5 0.28 19.96 4.4447 109 315 69.4 6433 74.4 0.347 20.26 4.3795 109 146 32.2 5359 62 0.624 20.904 4.2461 127 58 12.8 559 6.5 0.164 21.639 4.1034 142 194 42.7 4690 54.3 0.411 22.441 3.9586 161 368 81.1 5409 62.6 0.25 22.94 3.8735 78 150 33 6057 70.1 0.686 23.398 3.7988 78 116 25.6 2330 27 0.341 24.44 3.6391 75 305 67.2 5097 59 0.284 26.819 3.3215 68 206 45.4 4795 55.5 0.396 29.018 3.0745 56 109 24 4093 47.4 0.638 29.566 3.0188 82 43 9.5 341 3.9 0.135 31.022 2.8804 58 55 12.1 509 5.9 0.157 31.881 2.8047 49 48 10.6 482 5.6 0.171 32.338 2.7661 42 50 11 1360 15.7 0.462

Additional experiments with Form 1 of a compound of Formula (I) showed that when Form 1 was exposed to moisture (FIGS. 15A-15D), Form 1 formed non-stoichiometric or stoichiometric hydrates. The crystal lattice of Form 1 expanded when water was sorbed, giving rise to XRD peaks at ˜5, ˜7 and ˜11 degrees while maintaining the main XRD pattern. The hydrates of Form 1 of a compound of Formula (I) (Form 11) were fully reversible, and lost water when exposed to % RH of less than 20%, turning Form 11 to hydrated forms of Form 1 and to the anhydrous Form 1.

M. Form 13 and Form 12

The experiments that generated Form 13 and Form 12 are shown in Tables 30 and 32, below, respectively. Forms 12 and 13 are examples of non-stoichiometric hydrates of Form 1 that have between 1% and about 20% by weight water. XRD scans of Form 13 and Form 12 were taken (FIGS. 13A and 12A, respectively). The XRD peaks of Form 13 are shown in Table 31, below. DSC scans of Form 13 and Form 12 were also taken (FIGS. 13B and 12B, respectively). According to the DSC scan, Form 13 solids showed a wide endotherm between 50° C.-100° C., followed by a small exotherm at 278° C.; and a melting endotherm at 363° C. According to the DSC scan, Form 12 solids showed a wide endotherm between 50° C.-100° C., followed by a sharp exotherm at 283° C.; and a melting endotherm at 364° C.

The purity of the Form 13 sample was 98.8%; the KF of an undried Form 13 sample was 35.7%. A DVS scan of Form 13 solid showed a 17% water sorption at 90% RH (FIG. 13D). Form 13 converted to Form 1 upon drying.

A TGA scan of Form 13 solid showed a 1.9% weight loss before 100° C. (FIG. 13C).

Form 13 solid was heated in a DSC chamber to 170° C. (past the endotherm between 50-100° C.), and then scanned by XRD. A comparison of the first and the second XRD and DSC scans, after heating to 170° C., showed that Form 13 converted to Form 1. It can be concluded that the endotherm between 50-100° C. is due to bonded water.

Form 13 has a primitive orthorhombic crystal structure with the approximate dimensions: a [Å]=33.759, b [Å]=22.590, c [Å]=7.386 and an approximate volume cell of [Å³/cell]=5,632.5 and a space group defined as Pbca(61).

Form 13 solid was heated in a DSC chamber to 330° C. (past the endotherm/exotherm around 300° C.), and then scanned by XRD. A comparison of the first and the third XRD and DSC scans, after heating to 170° C., showed that Form 13 converted to Form 9. It can be concluded that the endotherm/exotherm is due to melting/crystallization events.

TABLE 30 Summary of experiments that generated Form 13 Form Solvent Temperature Wet Dry Form 13 MeOH RT Form 13 Form 1 MeOH/water 50° C. Form 13 Form 13 water RT Form 13 Form 1 water 50° C. Form 13 Form 13 Toluene/water RT Form 13 Form 1 Toluene/water 50° C. Form 13 Form 13 MA/water RT Form 13 Form 1 n-Butyl RT Form 13 Form 12 acetate/water n-Butyl 50° C. Form 13 Form 1 acetate/water Heptane 50° C. Form 13 Form 13 Heptane/water RT Form 13 Form 12 Heptane/water 50° C. Form 13 Form 1 n-Butanol/water RT Form 13 Form 13 n-Butanol/water 50° C. Form 13 Form 1 DCM 50° C. Form 13 Form 13 DCM/water RT Form 13 Form 1 DCM/water 50° C. Form 13 Form 1 Acetonitrile/water 50° C. Form 13 Form 13 IPAc/water 50° C. Form 13 Form 13 MtBE/water 50° C. Form 13 Form 13 MIBK/water 50° C. Form 13 Form 1 *Amount of water in binary solvents is 5%

TABLE 31 XRD peaks of Form 13 2-Theta d (A) BG Height I % Area I % FWHM 5.06 17.45 278 309 6.5 3685 4.8 0.203 6.379 13.8451 223 4743 100 76110 100 0.273 9.24 9.5632 164 1370 28.9 20018 26.3 0.248 11 8.0364 173 3445 72.6 51777 68 0.256 12.899 6.8574 195 173 3.6 3114 4.1 0.306 13.462 6.572 199 204 4.3 2376 3.1 0.198 14.159 6.2498 202 390 8.2 5424 7.1 0.236 15.56 5.6901 262 1335 28.1 19295 25.4 0.246 16.059 5.5145 302 1002 21.1 17561 23.1 0.298 16.841 5.26 313 774 16.3 7797 10.2 0.171 17.46 5.075 322 314 6.6 3863 5.1 0.209 18.419 4.8128 339 2354 49.6 29374 38.6 0.212 19.3 4.5951 357 210 4.4 8112 10.7 0.657 19.741 4.4935 329 1566 33 30236 39.7 0.328 20.202 4.3919 342 210 4.4 2880 3.8 0.233 20.84 4.2589 300 1054 22.2 18033 23.7 0.291 21.201 4.1873 284 964 20.3 15700 20.6 0.277 22.121 4.015 259 197 4.2 2208 2.9 0.191 23.2 3.8307 268 482 10.2 7844 10.3 0.277 24.42 3.642 280 1101 23.2 16244 21.3 0.251 24.839 3.5816 303 468 9.9 9306 12.2 0.338 25.219 3.5284 385 1093 23 16646 21.9 0.259 26.164 3.4032 359 357 7.5 5064 6.7 0.241 26.499 3.3609 402 317 6.7 7316 9.6 0.392 26.798 3.324 346 179 3.8 8025 10.5 0.762 27.339 3.2594 394 720 15.2 13063 17.2 0.308 27.639 3.2247 341 318 6.7 5673 7.5 0.303 28.799 3.0974 256 805 17 16756 22 0.354 29.902 2.9857 262 234 4.9 3508 4.6 0.255 31.234 2.8613 230 106 2.2 1473 1.9 0.236 31.96 2.798 226 308 6.5 3908 5.1 0.216 32.939 2.717 208 117 2.5 1444 1.9 0.21 33.962 2.6375 199 266 5.6 4617 6.1 0.295 34.917 2.5675 217 73 1.5 736 1 0.171

TABLE 32 Summary of experiments that generated Form 12 Form Solvent Temperature Wet Dry Form 12 Acetonitrile/water RT Form 12 Form 1 MeOH/water RT Form 12 Form 1 IPAc/water RT Form 12 Form 1 EA/water RT Form 12 Form 1 MtBE/water RT Form 12 Form 1 MIBK/water RT Form 12 Form 1 n-Butyl RT Form 13 Form 12 acetate/water Heptane/water RT Form 13 Form 12 MA/water 50° C. Form 12 Form 4 *Amount of water in binary solvents is 5%

N. Solvates 1-3

The experiments that generated Solvates 1, 2, and 3 are shown in Table 33, below. Solvates 1 and 2 solids were exposed to air overnight, and then analyzed by XRD. After the analysis, the solids were dried at 50° C. under vacuum, and then analyzed by XRD again.

After exposure to air overnight, Solvate 1 converted to low crystallinity; after drying at 50° C., the sample was still low crystallinity solid. After exposure to air overnight, the XRD pattern of Solvate 2 changed a little; after drying at 50° C., the form remained the same as the solid exposed to air overnight.

TABLE 33 Summary of experiments that generated solvates 1-3 Form Solvent Temperature Wet Dry Solvate 1 Acetone RT Solvate 1 Low crystallinity Solvate 2 Acetone/water RT Solvate 2 Form 4** Acetone 50° C. Solvate 2 Form 4** Solvate 3 EtOH/water RT Solvate 3 Form 2 *Amount of water in binary solvent is 5%

Example 2: Competitive Slurry Experiments Between Polymorph Forms

In order to find out the thermodynamic stability between the different forms, several competitive slurry experiments were carried out. Form 1, Form 2, Form 2*, Form 3, Form 4, Form 4*, Form 4**, Form 5, Form 7, Form 8, Form 9, Form 10, Form 11, Form 11*, and Form 13 (10 mg for each) was mixed and slurried in 2 mL of solvent at both RT and 50° C. The solids were slurried for 3-5 days and then analyzed by XRD. According to the analytical data, Form 2* was the most stable form in a MeOH, EtOH, and acetone system at both RT and 50° C. Form 4 or 4* was most stable in EA at RT and 50° C. Form 13 was most stable in water at RT and 50° C. Table 34 shows the XRD scan results from the competitive slurry experiments.

TABLE 34 XRD scan results of competitive slurry experiments Form after 3 days; Form after 5 days; Temperature Solvent wet/dry wet/dry RT MeOH Form 2*/Form 2* Form 2*/Form 2* EtOH Form 2*/Form 2* Form 2*/Form 2* Acetone Form 2*/Form 2* Form 2*/Form 2* EA Form 4/Form 4 Form 4/Form 4 water Form 13/Form 13 Form 13/Form 1&Form 13 50° C. MeOH Form 2*/Form 2* Form 2*/Form 2* EtOH Form 2*/Form 2* Form 2*/Form 2* Acetone Form 2*/Form 2* Form 2*/Form 2* EA Form 4/Form 4 Form 4*/Form 4* water Form 13/Form 13 Form 13/Form 13

In order to find out the thermodynamic stability between Form 13 and Form 9, several competitive slurry experiments were carried out. 15 mg of Form 1, Form 9 and Form 13 solid were mixed in 1 mL of toluene, IPAc, and n-butyl acetate, and slurried for 3 days at RT and 50° C.

The residual solid was analyzed by XRD. After a three-day slurry, it was difficult to tell which one was more stable between Form 13 and Form 9. The XRD scan results of the experiment is shown in Table 35, below.

TABLE 35 XRD scan results competitive slurry experiments Temperature Solvent Form after 3 days; wet/dry RT Toluene Form 13/Form 1 IPAc Form 9 + Form 13/Form 9 + Form 1 n-Butyl acetate Form 9 + Form 13/Form 9 + Form 1 50° C. Toluene Form 9 + Form 13/Form 9 + Form 1 IPAc Form 9/Form 9 n-Butyl acetate Form 9 + Form 13/Form 9 + Form 1

Other Embodiments

It is to be understood that the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. 

What is claimed is:
 1. A process for preparing a single-dose, ready-to-use formulation comprising a compound of Formula (I)

or a pharmaceutically acceptable salt or amorphous or polymorph form thereof, the process comprising: (a) providing an aqueous solution; (b) providing a slurry comprising a compound of Formula (I), or a pharmaceutically acceptable salt or amorphous or polymorph form thereof; (c) mixing the aqueous solution and the slurry to form a suspension; and (d) filling a container with the suspension to prepare a single-dose, ready-to-use formulation.
 2. The process of claim 1, wherein the aqueous solution is sterilized by filtration or by heat or by a combination of filtration and heat.
 3. The process of claim 1, wherein the slurry is sterilized by heat.
 4. The process of claim 1, wherein the mixing of the aqueous solution and the slurry to form a suspension is performed aseptically followed by aseptically filling the container.
 5. The process of claim 1, wherein the final single-dose, ready-to-use formulation is sterile.
 6. The process of claim 1, wherein the aqueous solution comprises a buffer.
 7. The process of claim 1, wherein the aqueous solution comprises an excipient.
 8. The process of claim 6, wherein the buffer is a phosphate buffer.
 9. The process of claim 8, wherein the phosphate buffer is selected from the group consisting of sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, potassium phosphate dibasic, and mixtures thereof.
 10. The process of claim 9, wherein the phosphate buffer is a mixture of sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate.
 11. The process of claim 7, wherein the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof.
 12. The process of claim 11, wherein the viscosity enhancer is a water-soluble cellulose derivative.
 13. The process of claim 11, wherein the surfactant is a polysorbate.
 14. The process of claim 12, wherein the water-soluble cellulose derivative is sodium carboxymethylcellulose.
 15. The process of claim 11, wherein the aqueous solution comprises about 0.01 g/kg to about 50 g/kg; about 0.1 g/kg to about 50 g/kg; about 1 g/kg to about 25 g/kg; about 1 g/kg to about 10 g/kg; about 1 g/kg to about 7.5 g/kg; about 1 g/kg to about 5.5 g/kg; about 1 g/kg to about 2.5 g/kg; about 2.5 g/kg to about 50 g/kg; about 5 g/kg to about 50 g/kg; about 10 g/kg to about 50 g/kg; about 25 g/kg to about 50 g/kg; about 2.5 g/kg to about 7.5 g/kg; about 5 g/kg to about 10 g/kg; or about 10 g/kg to about 20 g/kg of a viscosity enhancer.
 16. The process of claim 15, wherein the aqueous solution comprises about 5.5 g/kg of a viscosity enhancer.
 17. The process of claim 11, wherein the aqueous solution comprises about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant.
 18. The process of claim 17, wherein the aqueous solution comprises about 0.5 g/kg of a surfactant.
 19. The process of claim 11, wherein the aqueous solution comprises about 5.55 g/kg of sodium carboxymethylcellulose and about 0.5 g/kg of polysorbate
 80. 20. The process of claim 8, wherein the buffer is phosphate buffered saline.
 21. The process of claim 1, wherein the slurry comprises about 0.001 g/kg to about 5 g/kg; about 0.001 g/kg to about 2.5 g/kg; about 0.001 g/kg to about 1 g/kg; about 0.001 g/kg to about 0.75 g/kg; about 0.001 g/kg to about 0.5 g/kg; about 0.001 g/kg to about 0.25 g/kg; about 0.001 g/kg to about 0.01 g/kg; about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof.
 22. The process of claim 21, wherein the slurry comprises about 0.15 g/kg, about 0.35 g/kg, about 0.75 g/kg or about 1.15 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof.
 23. The process of claim 1, wherein the compound of Formula (I) comprises a polymorph form.
 24. The process of claim 23, wherein the polymorph used in the manufacturing is Form 1 and has an X-ray powder diffraction pattern comprising peaks at °2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2.
 25. The process of claim 24, wherein the compound used in the manufacturing of Formula (I) comprises a mixture of a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and Form
 1. 26. The process of claim 24, wherein the compound used in the manufacturing of Formula (I) comprises no more than about 5% by weight of other Forms of the compound of Formula (I).
 27. The process of claim 24, wherein the compound used in the manufacturing of Formula (I) comprises no more than about 1% by weight of other Forms of the compound of Formula (I).
 28. The process of claim 24, wherein the compound used in the manufacturing of Formula (I) comprises less than about 0.1% by weight of other Forms of the compound of Formula (I).
 29. The process of claim 1, wherein the slurry comprises an excipient.
 30. The process of claim 29, wherein the excipient comprises a surfactant.
 31. The process of claim 30, wherein the surfactant is a polysorbate.
 32. The process of claim 30, wherein the slurry comprises about 0.01 g/kg to about 5 g/kg; 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 5 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant.
 33. The process of claim 32, wherein the slurry comprises about 0.5 g/kg of a surfactant.
 34. The process of claim 31, wherein the slurry comprises about 0.15 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate
 80. 35. The process of claim 31, wherein the slurry comprises about 0.35 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate
 80. 36. The process of claim 31, wherein the slurry comprises about 0.75 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate
 80. 37. The process of claim 31, wherein the slurry comprises about 1.15 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate
 80. 38. The process of claim 1, wherein the aqueous solution is a filtered mixture.
 39. The process of claim 1, wherein the aqueous solution comprises a sterile diluent.
 40. The process of claim 1, wherein the aqueous solution is a first sterilized mixture; the slurry is a second sterilized mixture; and the process comprises mixing the first sterilized mixture and the second sterilized mixture.
 41. The process of claim 1, wherein the aqueous solution and slurry are mixed to form a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.01 mg/mL to about 2.0 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.5 mg/mL, about 0.01 mg/mL to about 0.2 mg/mL, or about 0.015 mg/mL to about 0.115 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.
 42. The process of claim 1, wherein the container comprises a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.005 mg/mL to about 2 mg/mL, about 0.001 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 1.8 mg/mL, about 0.015 mg/mL to about 0.115, about 0.025 mg/mL to about 1.6 mg/mL, about 0.05 mg/mL to about 1.5 mg/mL, about 0.075 mg/mL to about 1.25 mg/mL, about 0.1 mg/mL to about 1 mg/mL, or about 0.25 mg/mL to about 0.75 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.
 43. The process of claim 1, wherein the container is selected from the group consisting of a vial, a bottle, an ampule, and a syringe.
 44. The process of claim 43, wherein the vial is a glass vial or a plastic vial made of polyethylene, polypropylene, polyolefins, polyethylene terephthalate, polyethylene terephthalate G, poly(vinyl chloride), and mixtures thereof.
 45. The process of claim 1, wherein the container has a volume of 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL.
 46. The process of claim 1, wherein the container is a 3 mL polypropylene vial.
 47. The process of claim 1, wherein the mixing is done aseptically.
 48. The process of claim 1, wherein the filling is done aseptically.
 49. The process of claim 1, further comprising terminally sterilizing the filled container.
 50. A single-dose, ready-to-use formulation comprising a compound of Formula (I)

or a pharmaceutically acceptable salt or amorphous or polymorph form thereof, prepared by a process comprising: (a) providing an aqueous solution comprising water; (b) providing a slurry comprising a compound of Formula (I), or a pharmaceutically acceptable salt or amorphous or polymorph form thereof; (c) mixing the aqueous solution and the slurry to form a suspension; and (d) filling a container with the suspension to prepare the single-dose, ready-to-use formulation.
 51. The formulation of claim 50, wherein the aqueous solution comprises a buffer.
 52. The formulation of claim 50, wherein the aqueous solution comprises an excipient.
 53. The formulation of claim 51, wherein the buffer is a phosphate buffer.
 54. The formulation of claim 53, wherein the phosphate buffer is selected from the group consisting of sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, potassium phosphate dibasic, and mixtures thereof.
 55. The formulation of claim 54, wherein the phosphate buffer is a mixture of sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate.
 56. The formulation of claim 52, wherein the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof.
 57. The formulation of claim 56, wherein the viscosity enhancer is a water-soluble cellulose derivative.
 58. The formulation of claim 56, wherein the surfactant is a polysorbate.
 59. The formulation of claim 57, wherein the cellulose derivative is sodium carboxymethylcellulose.
 60. The formulation of claim 56, wherein the aqueous solution comprises about 0.0.01 g/kg to about 50 g/kg; about 1.0 g/kg to about 50 g/kg; about 1 g/kg to about 25 g/kg; about 1 g/kg to about 10 g/kg; about 1 g/kg to about 7.5 g/kg; about 1 g/kg to about 5.5 g/kg; about 1 g/kg to about 2.5 g/kg; about 2.5 g/kg to about 50 g/kg; about 5 g/kg to about 50 g/kg; about 10 g/kg to about 50 g/kg; about 25 g/kg to about 50 g/kg; about 2.5 g/kg to about 7.5 g/kg; about 5 g/kg to about 10 g/kg; or about 10 g/kg to about 20 g/kg of a viscosity enhancer.
 61. The formulation of claim 60, wherein the aqueous solution comprises about 5.5 g/kg of a viscosity enhancer.
 62. The formulation of claim 56, wherein the aqueous solution comprises about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant.
 63. The formulation of claim 62, wherein the aqueous solution comprises about 0.5 g/kg of a surfactant.
 64. The formulation of claim 56, wherein the aqueous solution comprises about 5.55 g/kg of sodium carboxymethylcellulose and about 0.5 g/kg of polysorbate
 80. 65. The formulation of claim 53, wherein the buffer is phosphate buffered saline.
 66. The formulation of claim 50, wherein the slurry comprises about 0.001 g/kg to about 5 g/kg; about 0.001 g/kg to about 2.5 g/kg; about 0.001 g/kg to about 1 g/kg; about 0.001 g/kg to about 0.75 g/kg; about 0.001 g/kg to about 0.5 g/kg; about 0.001 g/kg to about 0.25 g/kg; about 0.001 g/kg to about 0.01 g/kg; about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof.
 67. The formulation of claim 66, wherein the slurry comprises about 0.15 g/kg, about 0.35 g/kg, or about 1.15 g/kg of the compound of Formula (I), or a salt or amorphous or polymorph form thereof.
 68. The formulation of claim 50, wherein the compound of Formula (I) comprises a polymorph form.
 69. The formulation of claim 68, wherein the polymorph used in the manufacturing is Form 1 and has an X-ray powder diffraction pattern comprising peaks at °2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2.
 70. The formulation of claim 69, wherein the compound of Formula (I) comprises a mixture of a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and Form
 1. 71. The formulation of claim 69, wherein the compound of Formula (I) comprises no more than about 5% by weight of other Forms of the compound of Formula (I).
 72. The formulation of claim 69, wherein the compound of Formula (I) comprises no more than about 1% by weight of other Forms of the compound of Formula (I).
 73. The formulation of claim 69, wherein the compound of Formula (I) comprises less than about 0.1% by weight of other Forms of the compound of Formula (I).
 74. The formulation of claim 50, wherein the slurry comprises an excipient.
 75. The formulation of claim 74, wherein the excipient comprises a surfactant.
 76. The formulation of claim 75, wherein the surfactant is a polysorbate.
 77. The formulation of claim 75, wherein the slurry comprises about 0.01 g/kg to about 5 g/kg; 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 5 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; or about 1 g/kg to about 2 g/kg of a surfactant.
 78. The formulation of claim 77, wherein the slurry comprises about 0.5 g/kg of a surfactant.
 79. The formulation of claim 76, wherein the slurry comprises about 0.15 g/kg of polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate
 80. 80. The formulation of claim 76, wherein the slurry comprises about 0.35 g/kg of primarily polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate
 80. 81. The formulation of claim 76, wherein the slurry comprises about 1.15 g/kg of primarily polymorph Form 1 or a non-stoichiometric or stoichiometric hydrate of Form 1 having between 1% and about 20% by weight water and about 0.5 g/kg of polysorbate
 80. 82. The formulation of claim 50, wherein the aqueous solution is a filtered mixture.
 83. The formulation of claim 50, wherein aqueous solution comprises a sterile diluent.
 84. The formulation of claim 50, wherein the aqueous solution is a first sterilized mixture; the slurry is a second sterilized mixture; and the process comprises mixing the first sterilized mixture and the second sterilized mixture.
 85. The formulation of claim 50, wherein the aqueous solution and slurry are mixed to form a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.01 mg/mL to about 2.0 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.5 mg/mL, about 0.01 mg/mL to about 0.2 mg/mL, or about 0.015 mg/mL to about 0.115 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.
 86. The formulation of claim 50, wherein the container comprises a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.005 mg/mL to about 2 mg/mL, about 0.001 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 1.8 mg/mL, about 0.015 mg/mL to about 0.115, about 0.025 mg/mL to about 1.6 mg/mL, about 0.05 mg/mL to about 1.5 mg/mL, about 0.075 mg/mL to about 1.25 mg/mL, about 0.1 mg/mL to about 1 mg/mL, or about 0.25 mg/mL to about 0.75 mg/mL of the compound of Formula (I) or a salt or amorphous or polymorph form thereof.
 87. The formulation of claim 50, wherein the container is selected from the group consisting of a vial, a bottle, an ampule, and a syringe.
 88. The formulation of claim 87, wherein the vial is a glass vial or a plastic vial made of polyethylene, polypropylene, polyolefins, polyethylene terephthalate, polyethylene terephthalate G, poly(vinyl chloride), and mixtures thereof.
 89. The formulation of claim 50, wherein the container has a volume of 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL.
 90. The formulation of claim 89, wherein the container is a 3 mL polypropylene vial.
 91. The formulation of claim 50, wherein the mixing is done aseptically.
 92. The formulation of claim 50, wherein the filling is done aseptically.
 93. The formulation of claim 50, wherein the filled container is terminally sterilized.
 94. A method of treating osteoarthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the single-dose, ready-to-use formulation of claim
 50. 95. The method of claim 94, wherein administration is intra-articular.
 96. The method of claim 94, wherein the formulation is administered once.
 97. The method of claim 94, wherein the formulation is administered more than once with each injection separated by about 3 months to about 60 months.
 98. The method of claim 97, wherein the formulation is administered once monthly, every 3 months, 6 months, or 60 months. 